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Mycobacterium bovis (M. bovis) is the pathogen that causes bovine tuberculosis 
(bTB) in a wide range of host species including livestock and wildlife. Globally, the 
control of M. bovis infection is hindered by the existence of wildlife maintenance 
hosts. In South Africa, African buffaloes (Syncerus caffer) are considered 
maintenance hosts of bTB, and therefore control in this species will facilitate control 
in other sympatric wildlife species and livestock. With the limited availability of 
diagnostic tools and their suboptimal test performances to detect M. bovis infection in 
buffaloes, it is imperative to develop novel approaches to improve the detection of 
infected buffaloes.  
 
In this study, the QuantiFERON® TB-Gold (QFT) system in combination with the 
cattletype® IFN-gamma ELISA, the QFT interferon gamma (IFN-γ) release assay 
(IGRA), was shown to have high specificity but poor sensitivity in detecting M. bovis 
infection in buffaloes. The sensitivity of the QFT IGRA was improved by measuring 
the chemokine IFN-γ-inducible protein-10 (IP-10) in the QFT IP-10 release assay 
(IPRA). When both cytokines IFN-γ and IP-10 were measured in parallel in the QFT 
system, sensitivity was further improved and the specificity of the individual assays 
were maintained. The concentrations of IFN-γ and IP-10 in QFT tubes were used to 
predict the presence of macroscopic pathology in M. bovis-infected buffaloes. Lastly, 
the immunophenotyping of cattle whole blood identified cellular subsets of bovine 
leukocytes, however, the production of IP-10 in these cells was not confirmed.  
 
This study has demonstrated that the QFT system is a highly practical stimulation 




system and novel cattletype® IFN-gamma ELISA is an IGRA with high specificity 
that can be used to detect M. bovis infection in buffalo populations. The cytokine IP-
10 is a more sensitive biomarker than IFN-γ and when these two cytokines are 
measured in parallel in the QFT system, the detection of infected buffaloes is 
maximised, the specificity is high and the testing procedure is simplified. Finally, the 
magnitude of IP-10 and IFN-γ concentrations in QFT-processed whole blood can be 






Die patogeen Mycobacterium bovis (M. bovis) veroorsaak beestuberkulose (bTB) in 
‘n wye reeks gashere wat vee en wild insluit. Wereldwyd word die beheer van M. 
bovis infeksie bemoeilik as gevolg van die teenwoordigheid van 
nstandhoudingsgashere in die wildsbevolking. Afrikabuffels (Syncerus caffer) word 
as belangrike instandhoudingsgashere van bTB in Suid Afrika beskou met die gevolg 
dat siektebeheer in hierdie spesie die beheer van bTB in ander simpatriese wildsoorte 
en vee sal fasiliteer. Met die beperkte beskikbaarheid van diagnostiese tegnieke en 
gepaardgaande suboptimale toets prestasie, het dit dus noodsaaklik geword om nuwe 
benaderings wat verbeterde opsporing van M. bovis in buffels sal teweegbring, te 
ontwikkel. 
 
Hierdie studie het getoon dat die QuantiFERON®-TB Gold (QFT) interferon gamma 
(IFN-γ) vrystellingstoets (IGRA), ’n kombinasie van die QFT sisteem en die 
cattletype® IFN-gamma ELISA, hoë spesifisiteit maar swak sensitiwiteit vir die 
opsporing van M. bovis in buffels het. Die sensitiwiteit van die QFT IGRA kon 
verhoog word deur die chemokien interferon gamma-geïnduseerde proteïen-10 (IP-
10) te meet met die QFT IP-10 vrystellingstoets (IPRA). Deur beide IFN-γ en IP-10 in 
parallel te meet in die QFT sisteem, is die sensitiwiteit verder verbeter sonder verlies 
van spesifisiteit van die toets. Die konsentrasies van IFN-γ en IP-10 in QFT buise kon 
die teenwoordigheid van makroskopiese letsels in M. bovis besmette buffels voorspel. 
Laastens is subgroepe van beesleukosiete deur immunofenotipering van heel 
beesbloed geidentifiseer, alhoewel die produksie van IP-10 deur hierdie selle nie 





Hierdie studie het gedemonstreer dat die QFT sisteem ‘n uiterse praktiese 
stimulasieplatform is om M. bovis met spesifisiteit te diagnoseer. Die kombinasie van 
die QFT sisteem met die nuwe cattletype® IFN-gamma ELISA lewer ‘n hoogs 
spesifisiteit IGRA wat gebruik kan word om M. bovis infeksie in buffelbevolkings te 
diagnoseer. Die chemokien IP-10 is ‘n meer sensitiewe biomerker as IFN-γ, maar 
wanneer hulle in parallel gemeet word in die QFT sisteem, lei dit tot die maksimum 
opsporing van besmette buffels met ‘n hoë spesifisiteit terwyl die toetstegniek 
vereenvoudig is. Ter afsluiting, die vlak van IP-10 en IFN-γ konsentrasies wat in heel 
beesbloed in die QFT sisteem gemeet is, kan as aanwyser dien om siekteletsels in M. 
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Chapter 1 : General Introduction 
 
This introductory chapter aims to give a literature summary of the host, pathogen and 
diagnosis of Mycobacterium bovis (M. bovis) infection. Furthermore, this chapter will 
highlight the justification for a study investigating novel approaches to detect M. bovis 







Mycobacterium bovis  
Mycobacterium bovis (M. bovis) is a member of the Mycobacterium tuberculosis complex 
(MTBC), a group of genetically related mycobacterium species that cause tuberculosis (TB) 
in a range of mammals (Gagneux, 2018). Of all MTBC members, M. bovis has the widest 
host range and causes bovine tuberculosis (bTB) in domestic animals, livestock, wildlife and 
humans (Michel et al., 2006). Globally, the eradication of M. bovis is hampered by the 
existence of wildlife reservoirs that serve as constant sources of infection (Fitzgerald and 
Kaneene, 2013).  
 
M. bovis in South African wildlife  
In South Africa (SA), two of the largest wildlife reserves, the Kruger National Park (KNP) 
and Hluhluwe iMfolozi Park (HiP), as well as a number of smaller wildlife reserves, have 
been declared endemic for M. bovis (Michel et al., 2006; Hlokwe et al., 2016). Many of these 
wildlife reserves, including KNP and HiP, are adjacent to communal lands where livestock 
graze freely (de Garine-Wichatitsky et al., 2013; Hlokwe et al., 2014). The wildlife and 
livestock are only separated by single or double fences, which are frequently damaged by 
elephants, humans or floods (Jori et al., 2011). Therefore, spillover transmission of M. bovis 
has been documented in South Africa from livestock to wildlife and back, at this livestock-
wildlife interface (de Lisle et al., 2002; Musoke et al., 2015). 
 
Mycobacterium bovis infection in African buffaloes  
In SA, African buffaloes (Syncerus caffer) are the most recognised wildlife maintenance 
hosts of M. bovis. Transmission of M. bovis has been documented between buffaloes in the 
KNP and neighbouring rural cattle (Musoke et al., 2015) as well as in KNP from buffaloes to 





in buffaloes is a key factor in controlling infection in livestock and sympatric wildlife 
species. Specifically, accurate diagnosis of M. bovis infection in buffaloes is required to 
identify infected animals to remove them from the population to limit the transmission of M. 
bovis (i.e. test-and-cull programmes) and legally move buffaloes within SA to limit the 
geographic spread of M. bovis. However, diagnosis of M. bovis infection in buffaloes is 
limited by the tools available and their suboptimal test performances. 
 
Single comparative intradermal tuberculin test 
In buffaloes, the cell-mediated immune response is the primary and earliest response to 
develop after infection with M. bovis. Thus, early diagnosis of M. bovis infection relies on 
using in vitro and in vivo assays to detect and quantify cell-mediated immunity (CMI) in 
response to mycobacterial antigens (Goosen et al., 2014a). The in vitro single comparative 
intradermal tuberculin test (SCITT) measures local delayed-type hypersensitivity reaction 
(after approximately 72 hours) in response to intradermal injection of purified protein 
derivative (PPD) namely M. bovis PPD (PPDb) and Mycobacterium avium PPD (PPDa), 
which is included as a comparative antigen (Schiller et al., 2010). The SCITT can be 
performed with limited infrastructure, does not require the stimulation or transportation of 
blood samples to accredited laboratories under time and temperature constraints, and results 
are directly linked to individual buffaloes, limiting the wrong classification of test-positive or 
negative animals. However, the SCITT requires buffaloes to be chemically immobilised 
twice and kept confined during this time. Furthermore, the interpretation of assay results may 
be subjective and the administration of PPDs may affect future test-results (Clarke et al., 
2018). Despite these disadvantages, the SCITT remains the only assay approved in SA to 







The standard Bovigam® interferon gamma (IFN-γ) release assay (IGRA) (Prionics AG, 
Schlieren-Zurich, Switzerland) is the in vitro alternative to the SCITT. Whole blood is 
stimulated overnight with PPDs, like those used in the SCITT, after which the biomarker 
IFN-γ, a cytokine produced by the activation of sensitised T-lymphocytes, is detected and 
quantified using an enzyme-linked immunosorbent assay (ELISA) (Goosen et al., 2014b). 
The specificity (Sp) of the standard Bovigam® IGRA can be improved by the replacement of 
PPDs with specific mycobacterial antigens. The Bovigam® peptide IGRAs, Bovigam® PC- 
EC and Bovigam® PC-HP, use peptides simulating early secretory antigen target 6 kD 
(ESAT-6) and culture filtrate protein 10 kD (CFP-10), and Rv3615 and three additional 
proprietary mycobacterial antigens, respectively, as stimulating antigens (Goosen et al., 
2014b). The use of specific antigens is also more standardised than PPDs, as PPDs may vary 
between batches and sources (Monaghan et al., 1994; de la Rua-Domenech et al., 2006). 
 
QuantiFERON®-TB Gold system 
The QuantiFERON®-TB Gold (QFT) system (Qiagen, Venlo, Limburg, Netherlands) is an 
innovative whole blood stimulation platform using specific mycobacterial antigens in an 
easy-to-use, field-friendly format. The QFT system comprises of three tubes; i) Nil tube 
containing saline (unstimulated control), ii) TB antigen tube containing peptides simulating 
antigens ESAT-6, CFP-10 and TB7.7(p4) (stimulated) and iii) mitogen tube containing 
phytohemagglutinin (positive control). Whole blood can be collected directly into each tube 
after which tubes are incubated at 37 °C overnight, plasma harvested and cytokine 
biomarkers measured by ELISA. The practicality of the tubes together with the use of 
specific antigenic peptides make this system highly suitable for detecting M. bovis infection 





detect M. bovis infection in buffaloes, an IGRA using QFT stimulation tubes and an in-house 
bovine-specific IFN-γ ELISA. The manufacturers of the QFT system (Qiagen) have since 
developed the commercially available cattletype® ruminant-specific IFN-gamma ELISA. 
Furthermore, Qiagen has improved the performance of the QFT system for human 
application by including an additional antigen tube (TB2) and modifying the antigens in the 
original TB antigen tube (TB1). The new QFT Plus system is comprised of four tubes; i) Nil 
tube, ii) TB1 antigen tube containing peptides simulating antigens ESAT-6 and CFP-10, ii) 
TB2 antigen tube containing the same peptides as those in TB1 plus shorter peptides 
simulating antigens ESAT-6 and CFP-10, and iii) mitogen tube (Theel et al., 2018).  
  
IP-10 as biomarker of infection  
The cytokine IFN-γ is the archetypal biomarker of the cell-mediated immune response but 
several additional candidate biomarkers have been evaluated to detect M. bovis infection in 
buffaloes (Goosen et al., 2014a). Of the biomarkers assessed, IFN-γ-inducible protein-10 (IP-
10) was identified as the chemokine that demonstrated a similar ability as IFN-γ to 
differentiate between M. bovis-infected and uninfected buffaloes (Goosen et al., 2014a). 
Furthermore, IP-10 was described as a sensitive biomarker of antigen recognition in whole 
blood stimulation assays, namely the QFT IP-10 release assay (IPRA), to detect M. bovis 
infection in buffaloes (Goosen et al., 2015).  
 
IP-10 as an indicator of pathology  
In humans and cattle, the utility of IP-10 as a biomarker of Mycobacterium tuberculosis 
(Mtb) and M. bovis infection, respectively, is compromised by elevated levels of IP-10 in 
some unstimulated control tubes (Whittaker et al., 2008; Parsons et al., 2016). Elevated IP-10 





and unstimulated control and this may cause a false-negative test result. In humans, elevated 
levels of IP-10 in unstimulated control tubes may be associated with active TB and has been 
used to distinguish Mtb-infected and uninfected patients (Whittaker et al., 2008; Chen et al., 
2011). Moreover, IP-10 is included in a serum (ex vivo) biomarker signature for the diagnosis 
of active TB in humans (Hussain et al., 2010; Chegou et al., 2016). These studies suggest that 
elevated levels of IP-10 in unstimulated buffalo whole blood samples may indicate the extent 
of disease in animals and therefore, this requires additional investigation. Furthermore, 
insight into the production of IP-10 in buffaloes may shed light on the mechanisms that cause 
elevated levels of IP-10 in the unstimulated control.  
 
Immunobiology of IP-10 
The immunobiology of IP-10 production in both cattle and buffaloes is unknown, while in 
humans, IP-10 production has been extensively explored. In humans, the chemokine IP-10 
has been reported to be produced by neutrophils (Gasperini et al., 1999), macrophages 
(Agostini et al., 2001), monocytes (Vargas-Inchaustegui et al., 2010) and B lymphocytes 
(Hoff et al., 2015). A greater understanding of the cells involved in IP-10 production in 
bovids is required to explain elevated IP-10 levels observed and may allow the effective use 
and interpretation of this chemokine as a diagnostic marker of M. bovis infection. Since 
obtaining cattle whole blood samples is easier than obtaining buffalo whole blood samples, a 
pilot study conducted in cattle using bovid-specific reagents may be useful to develop the 
methods required to study IP-10 production, which can then be applied to buffaloes.  
 
Justification of study 
African buffaloes are maintenance hosts of M. bovis in SA and therefore a key species on 





wildlife species and livestock (de Vos et al., 2001). However, the detection of M. bovis 
infection in buffaloes is confounded by the suboptimal performances and logistical 
drawbacks associated with currently available diagnostic tests. New and established CMI-
based assays utilised in novel ways, may improve the detection of infection in buffaloes and 
simplify testing procedures. Evaluating data from each component of the cytokine assays in 
addition to the final assay result of these tests may also allow additional interpretation with 
regards to presence of disease, as observed in humans (Whittaker et al., 2008; Chegou et al., 
2016). Moreover, calculating the M. bovis infection prevalence of a herd based on 
mycobacterial culture, and subsequently calculating predictive values of the assays will 
provide greater insight into the test performance of new and established CMI-based assays. 
Testing different herds with varying infection prevalences and bTB history will allow the 
performances of assays to be determined in different settings. Furthermore, investigating the 
immunobiology of IP-10 in cattle, which has not yet been done, will provide a platform for 
future studies in buffaloes to understand the production of IP-10 and assess IP-10 as a 
potential biomarker of M. bovis infection and bTB disease.  
 
Study aims and objectives 
 
Aim 
To improve the detection of M. bovis infection in African buffaloes (Syncerus caffer) using 
novel diagnostic approaches. 
 
Objectives 
1. To evaluate novel and established assays of CMI, utilised in innovative ways, for 





2. To determine the impact of bTB pathology on interpretation of assay results in M. bovis-
infected buffaloes. 
3. To use flow cytometry to investigate IP-10 production in cattle. 
 
Ethical approval for this study was granted by the Stellenbosch University Animal Care and 
Use committee (SU-ACUD15-00065, SU-ACUD15-00072 and SU-ACUD16-00097) 
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Chapter 2 : Wildlife tuberculosis in South Africa 
 







The Mycobacterium tuberculosis complex (MTBC) is a genetically related group of 
mycobacteria that cause tuberculosis in wildlife. The MTBC have a wide mammalian host 
range including ungulates, carnivores, primates, and small rodents. Wildlife tuberculosis in 
South Africa threatens management strategies and conservation efforts to protect wildlife. 
Furthermore, the human/wildlife/livestock interface allows multi-directional transmission 
events, adding to the complexity of this disease. The epidemiology of MTBC members that 
infect free-ranging wildlife species in South Africa and the diagnostic tools available to 





1. Introduction  
Tuberculosis (TB) is an infectious disease caused by members of the Mycobacterium 
tuberculosis complex (MTBC): Mycobacterium africanum (M. africanum), Mycobacterium 
bovis (M. bovis), Mycobacterium canetti (M. canetti), Mycobacterium caprae (M. caprae), 
Mycobacterium microti (M. microti), Mycobacterium mungi (M. mungi), Mycobacterium 
orygis (M. orygis), Mycobacterium pinnipedii (M. pinnipedii), Mycobacterium suricattae (M. 
suricattae), Mycobacterium tuberculosis (Mtb), chimpanzee bacillus and dassie bacillus 
(Gagneux, 2018). Despite exhibiting low deoxyribonucleic acid (DNA) sequence diversity, 
the MTBC organisms are epidemiologically unique and have a diverse mammalian host range 
including domestic animals, livestock, wildlife and humans (Hlokwe et al., 2014; Dippenaar 
et al., 2017).  
 
In South Africa (SA), the existence of extensive human/wildlife/livestock interfaces pose a 
risk of MTBC transmission between these groups. The risk of spillover of TB from wildlife 
to domestic livestock may have regulatory consequences and subsequent trade restrictions. In 
addition, detection of wildlife TB can lead to quarantine of wildlife premises and threaten 
conservation and tourism, which can have extensive environmental and socio-economic 
implications for SA (Meiring et al., 2018). Wildlife reservoirs serve as recurrent sources of 
infection as disease persists in these species, and can be maintained in the absence of new 
introductions of infection, posing a threat for reinfection of livestock and other sympatric 
wildlife species (Fitzgerald and Kaneene, 2013). 
 
With the advent of new techniques to detect MTBC infection in wildlife, our understanding 
of TB continues to evolve. Recent additions to our knowledge of M. bovis, Mtb, dassie 





wildlife in SA, are reviewed in this chapter with a focus on new developments in 
epidemiology and diagnostics. 
 
2. Epidemiology of M. bovis infection in wildlife in SA  
Mycobacterium bovis has the broadest host range of all MTBC organisms and is responsible 
for the most common form of wildlife TB in SA, bovine TB (bTB). Twenty-four wildlife 
species have been confirmed to be infected with M. bovis in SA (Table 2.1), with some of the 
new species added being on the IUCN Red List of Threatened Species™ 
(http://www.iucnredlist.org/). These include cases in the African wild dog (Lycaon pictus), 
black (Diceros bicornis) and white rhinoceros (Ceratotherium simum), giraffe (Giraffa 
camelopardalis) and African elephant (Loxodonta africana) (Miller et al., 2017a, 2018a, 
unpubl. data, Higgitt et al., 2018; Hlokwe et al., 2019) (Figure 2.1).  
 
Infected wildlife are classified as either maintenance or dead-end hosts, depending on the 
dynamics of the infection (Renwick et al., 2007). African buffaloes (Syncerus caffer) and 
greater kudu (Tragelaphus strepsiceros) are recognised maintenance hosts of M. bovis, while 
warthogs (Phacochoerus africanus) may be maintenance hosts under certain conditions, i.e. 
increased population densities (de Vos et al., 2001; Keet et al., 2001; Roos et al., 2016). 
Other wildlife species and their roles as hosts in infection and transmission are not yet fully 
understood. 
 
2.1. Routes of infection and transmission  
Although TB is described as a respiratory disease, the outcome of infection varies in different 
species and also depends on the route of infection. For example, the spillover of M. bovis 





Table 2.1 Free-ranging wildlife species confirmed to be infected with Mycobacterium bovis in South Africa, detailed by the location of the 
infected species with references. Superscript numbers correspond to species in Figure 2.1. 
Species Common name KNPa GKNPb HiPc KZNd MGRe SNRf Other locations Reference/s 
Syncerus caffer1 African buffalo  √ √ √ √ √ √ Mpumalanga Rodwell et al., 2001; Hlokwe et al., 2011, 2016 
Lycaon pictus2 African wild dog  √ - √ - - - - Higgitt, 2018; Higgitt et al., 2019 
Mungos mungo3 Banded mongoose  √ - - - - - - Brüns et al., 2017 
Diceros bicornis4 Black rhinoceros  √ - - - - - - Miller et al., 2017a 
Connochaetes taurinus5 Blue wildebeest  - √ - - - - - Hlokwe et al., 2014 
Tragelaphus scriptus6 Bushbuck √ - - - - - - Michel et al., 2015 
Potamochoerus porcus7 Bush pig  - - √ - - - - Michel et al., 2009; Hlokwe et al., 2011 
Papio ursinus8 Chacma baboon  √ - √ √ - - Limpopo Keet et al.,1996, 2000; Michel et al., 2009, 2013; Hlokwe et al., 2016 
Acinonyx jubatus9 Cheetah  √ √ - - - - - Keet et al., 1996; Michel et al., 2009 
Syvicapra grimmia10 Common duiker  - - - - - - Eastern Cape Paine and Martinaglia, 1929 
Taurotragus oryx11 Eland  - √ √ - - - - Michel et al., 2006, 2009 
Loxodonta africana12 Elephant  √ - - - - - - Miller unpubl. data 
Giraffa camelopardalis13 Giraffe  √ - - - - - - Hlokwe et al., 2019 
Tragelaphus strepsiceros14 Greater kudu √ √ √  √ - √ Addo Elephant Park Paine and Martinaglia, 1929; Bengis et al., 2001; Hlokwe et al., 2016  
Mellivora capensis15 Honey badger  √ - √ - - - - Michel et al., 2009 
Aepyceros melampus16 Impala  √ - - - - - - Michel et al., 2009 
Genetta tigrina17 Spotted genet  √ - √ - - - - Michel, 2002; Michel et al., 2009 
Panthera pardus18 Leopard  √ √ √ - - √ - Michel, 2002; Michel et al., 2009 
Panthera leo19 Lion  √ - √ √ √ √ - Bengis et al., 1996; Michel et al., 2009 
Tragelaphus angasii20 Nyala  - - - - - - Gauteng Hlokwe et al., 2016 
Antidorcas marsupialis21 Springbok  - - - - - - - Michel et al., 2015 
Crocuta crocuta22 Spotted hyaena  - √ - - - - - Michel et al., 2009 
Phacochoerus aethiopicus23 Warthog  √ √ √ √ - - - Roos et al., 2016 
Ceratotherium simum24 White rhinoceros  √ - - - - - - Miller et al., 2018a 
a Kruger National Park 
b Greater Kruger National Park 
c Hluhluwe iMfolozi Park 
d KwaZulu-Natal 
e Madikwe Game Reserve 





(Renwick et al., 2007), which is supported by the location of bTB pathology in the head and 
mesenteric lymph nodes of carnivores (Maas et al., 2013). Although carnivores are usually 
considered dead-end hosts, lions may serve as reservoirs of disease in some cases, as 
respiratory shedding of viable M. bovis has been documented in this species (Miller et al., 
2015a). Omnivores, namely chacma baboons (Papio ursinus), warthogs and honey badgers 
(Mellivora capensis) may also become infected via scavenging on infected carcasses (Michel 
et al., 2006; Renwick et al., 2007). Therefore, the epidemiology of bTB in SA is complicated 
by the presence of multiple susceptible hosts and potential routes of infection. 
 
The behaviour and social structure of different species may influence potential routes of 
infection and transmission. Social wildlife species namely buffaloes, warthogs, wild dogs and 
antelope may become infected via direct contact. Wild dogs may transmit bacteria when they 
regurgitate food for their pups or when they characteristically lick each other’s mouths 
(Woodroffe et al., 1997). This is supported by a study in which M. bovis was cultured from 
wild dog oropharyngeal swabs (Higgitt et al., 2019). Warthogs are communal burrowers and 
cooperative breeders which may increase their risk of intra and inter-species transmission 
(Roos, 2018).  
 
In less social species, namely giraffe, cheetah (Acinonyx jubatus), and some ungulate species, 
transmission of M. bovis may be indirect and via contaminated environmental sources by 
sharing grazing and water sources with maintenance hosts. Due to presence of bTB pathology 
in the lungs of white rhinoceroses, it was proposed that the source of M. bovis infection was 
via aerosolization of mycobacteria from a contaminated environment; however, a study 
reported rare shedding of bacilli during localised M. bovis infection (Michel et al., 2017; 





infection in an M. bovis-infected black rhinoceros (Miller et al., 2017a). Environmental 
contamination is believed to be the predominant cause of interspecies transmission of M. 
bovis between cattle and European badgers (Meles meles) in the United Kingdom (Drewe et 
al., 2013) and cattle and European wild boar (Sus scrofa) in Spain (Barasona et al., 2014), 
which is feasible since M. bovis is able to persist in the environment for up to 15 months 
(Sweeney et al., 2007). However, very limited information is available on routes of 
transmission of M. bovis in wildlife and on the role of environmental contamination in the 
epidemiology of bTB in SA. 
 
Figure 2.1 Index cases of Mycobacterium bovis infection in free-ranging wildlife species in 
South Africa over the last century (Dawson, n.d.). Species correspond to the superscript 
numbers in Table 2.1. 
 
2.2. Geographic distribution and spread 
Initially, M. bovis in wildlife was restricted to specific geographic regions within SA, but 





1928 in the Eastern Cape (Paine and Martinaglia, 1929), three of SA’s largest wildlife 
reserves, the Hluhluwe iMfolozi Park (HiP), Kruger National Park (KNP) and Madikwe 
Game Reserve (MGR) are endemic for M. bovis (Bengis et al., 1996; Jolles, 2004; Hlokwe et 
al., 2016). More recently, a number of smaller public and private reserves in KwaZulu-Natal 
(KZN) and Greater Kruger National Park (GKNP) have had confirmed cases of M. bovis 
infection in wildlife species (Figure 2.2) (Hlokwe et al., 2016). Movement of infected 
wildlife is a risk factor in the geographical spread of TB. However, there are few regulatory 
requirements in SA that address this risk, other than issuing quarantine notices to infected 
premises. The Veterinary Procedural Notice (VPN), which outlines testing requirements for 
the legal movement of buffaloes is under revision by Department of Agriculture, Forestry, 
and Fisheries (DAFF) at the time of this writing (DAFF, 2017). However, there are no other 
requirements for TB testing of wildlife species in SA prior to translocations.  
 
 
Figure 2.2 The geographical distributions of Mycobacterium bovis during the last century in 





Translocations are key to conservation efforts in SA. For example, predator populations, 
including wild dog and cheetah, are managed as metapopulations in SA by moving animals 
between reserves to maintain population growth and genetic diversity (Davies-Mostert et al., 
2015; Buk et al., 2018). Efforts to protect rhinoceroses from poaching also require the 
movement of animals from large populations in KNP and HiP to other reserves (Miller et al., 
2018a). However, the presence of bTB restricts movement of animals and lack of validated 
diagnostic tests confound conservation efforts, although movement of untested animals may 
contribute to the geographical spread of TB in SA. 
 
2.3. Susceptibility 
Susceptibility to M. bovis infection and subsequent outcomes of infection and disease differ 
between wildlife hosts. Ungulates are generally considered susceptible to infection with 
progression to classical granulomatous disease. Enlarged parotid lymph nodes are a clinical 
sign of bTB infection in kudu (Keet et al., 2001) while elephants only show clinical signs at 
advanced stages of disease (Miller et al., 2019). A study by le Roex et al. (2013) identified 
gene polymorphisms associated with disease susceptibility in African buffaloes. 
Susceptibility to infection and disease may differ between rhinoceros species based on 
extrapolation from historical cases suggesting browser species (black rhinoceroses) may be 
more likely to acquire and develop disease than grazing species, such as white rhinoceroses 
(Miller et al., 2017b). The macroscopic pathology of bTB in a black rhinoceros was similar to 
that reported in captive rhinoceroses (pulmonary disease), while white rhinoceroses appear to 
be able to limit disease progression, based on the very localised disease in naturally and 






Carnivores are generally considered to be susceptible to infection but may not develop 
disease. Immune sensitisation to M. bovis has been detected in spotted hyenas (Crocuta 
crocuta) (Higgitt et al., 2017), but there has been no evidence of clinical disease, which 
suggests that spotted hyenas may exhibit a unique and robust immune system that makes 
them less susceptible (Harrison et al., 2004). In contrast to hyenas, lions, leopards (Panthera 
pardus), and cheetah are susceptible to M. bovis infection as well as bTB disease and can 
have high morbidity and mortality rates (Keet et al., 1996). This is in agreement with other 
infectious diseases such as anthrax, where hyenas are not susceptible to disease but wild 
felids develop clinical signs and death (Lembo et al., 2011).  
 
Susceptibility of small wild mammals is generally unknown. In banded mongooses (Mungos 
mungo), M. bovis infection and disease has been reported but in general, insufficient 
information is available regarding the susceptibility to infection and disease in smaller 
mammals and requires further investigation (Brüns et al., 2017).  
 
3. Epidemiology of Mtb infection in wildlife in SA 
Mycobacterium tuberculosis is the primary pathogen that causes TB in humans, although 
globally there are numerous reports of Mtb infection and disease in captive animals (Michel 
et al., 2003; Miller et al., 2018b). In SA, reports of Mtb infection in free-ranging wildlife 
species are limited to an African elephant and chacma baboons, which may be primarily due 
to indirect transmission (Table 2.2).  
 
In 2016, the first fatal case of TB in a free-ranging African elephant due to Mtb was 
discovered in the KNP (Miller et al., 2019). Extensive disease was present upon necropsy 





The source of infection may have been indirect contact through human-derived contaminated 
food or infectious biological discharge, or inadequate treatment of waste water, human waste 
from visitors, staff, or human settlements along the reserve’s boundary fences. Alternatively, 
the elephant may have had direct contact with an infected animal, although unlikely (Miller et 
al., 2019). Baboons are also known to go through human waste at picnic sites and houses, 
which may be the source of Mtb infection in this species (Drewe et al., 2012). In SA, as the 
human population increases and conservation areas become more fragmented, wildlife 
habitats are being encroached upon and together with the high burden of Mtb in the country, 
increased transmission of Mtb at human/wildlife interfaces can be expected (Michel et al., 
2013). Globally, wildlife conservation is threatened by the increased transmission of diseases 
between humans and wildlife (Jones et al., 2008).  
 
4. Epidemiology of Dassie bacillus, M. mungi, M. suricattae, and M. orygis infection 
in wildlife in SA  
In SA, three members of the MTBC have been confirmed in only a single species; dassie 
bacillus in rock hyraxes (Procavia capensis), M. mungi in banded mongooses, and M. 
suricattae in meerkats (Suricata suricattae) (Table 2.2). These three MTBC members 
evolved from a common ancestor, M. africanum, individually within different hosts (Clarke 
et al., 2016a). Originating from the same common ancestor, M. orygis has only been 
identified in buffaloes in SA (Gey van Pittius et al., 2012) (Table 2.2), although M. orygis has 
been reported in captive antelope and humans elsewhere (van Soolingen et al., 1994; van 








4.1. Dassie bacillus 
In 1954, dassie bacillus was isolated in rock hyraxes for the first time in the Eastern Cape in 
SA (Wagner et al., 1958). Since then, numerous cases of TB in rock hyraxes have been 
documented around SA, suggesting the widespread distribution of this organism (Clarke et 
al., 2016a). Dassie bacillus appears to be transmitted via the respiratory tract in rock hyraxes 
as pathology is primarily observed in the lungs (Parsons et al., 2008). Susceptibility to 
disease may vary in rock hyraxes as some animals with severe disease exhibit clinical signs, 
while others remain asymptomatic (Cousins et al., 1994; Parsons et al., 2008).  
 
Table 2.2 Mycobacterium tuberculosis complex (MTBC) index cases in free-ranging wildlife 
in South Africa, detailed by the year and location of the affected species with references. 
MTBC Species Year  Location Reference/s 
Mtba Papio ursinus 1998 Western Cape  Parsons et al., 2009 
Loxodonta africana 2018 Kruger National Park Miller et al., 2019 
Dassie bacillus Procavia capensis 1954 Eastern and Western Cape Wagner et al., 1958; Parsons et al., 2008  
M. mungic Mungos mungo 1999 Botswana and Zimbabwe  Alexander et al., 2010; Fitzermann, 2017 
M. surricattaeb Suricata suricattae 1990s Northern Cape  Drewe, 2010; Parsons et al., 2013 
M. orygisd Syncerus caffer 2007 KwaZulu-Natal  Gey van Pittius et al., 2012 
a Mycobacterium tuberculosis 
b Mycobacterium suricattae 
c Mycobacterium mungi 
d Mycobacterium orygis 
 
4.2. M. mungi 
In 1999, TB due to M. mungi was reported in banded mongooses in the Chobe National Park 
in Botswana, on the northern border of SA, and between 1999 and 2010 additional outbreaks, 
causing rapidly progressive disease in mongooses, were documented in this region as well as 





documented in SA, spillover from Zimbabwe to SA is expected. Due to erosion of the nasal 
planum in infected mongooses, the likely route of entry is the nasal cavity (Alexander et al., 
2016). However, shedding of M. mungi from anal gland secretions suggests an additional 
route of transmission in this species. Furthermore, a study demonstrated an association 
between mongooses foraging in garbage and increased risk of acquiring TB when bacteria 
enter broken skin incurred through injuries (Flint et al., 2016). 
 
4.3. M. suricattae  
The first confirmatory diagnosis of TB in meerkats in SA was in 2001, in a long-term study 
population, the Kalahari Meerkat Project in the Northern Cape (Drewe et al., 2009; Drewe, 
2010). The causative organism was later identified as M. suricattae (Parsons et al., 2013). 
There have been numerous additional reports of TB fatalities in this population of meerkats 
(Clarke et al., 2016b). Several sources of M. suricattae infection and transmission routes have 
been suggested in meerkats. Being a strongly social species, respiratory infection may occur 
when in close contact while transmission via wounds during grooming or fighting has also 
been proposed (Drewe, 2010; Drewe et al., 2011). Meerkats appear to be very susceptible to 
disease and present with typical granulomas in the lungs and other organs, with rapid disease 
progression to death (Alexander et al., 2002). A study reported older animals may be at a 
greater risk of disease than younger animals and suggested group and individual level risk 
factors may exist for developing disease in meerkats (Patterson et al., 2017). As clinical signs 
associated with TB are more often seen in meerkats and banded mongooses than rock 
hyraxes, the virulence of M. suricattae and M. mungi is suggested to be higher than for the 







4.4. M. orygis  
In 2007, M. orygis, then classified as oryx bacillus, was identified in a buffalo with typical 
TB lesions on a private wildlife reserve in KZN (Gey van Pittius et al., 2012). Since then, no 
additional cases of M. orygis infection in buffaloes or other wildlife species have been 
reported in SA, although the limited genetic speciation of isolated MTBC members may 
contribute to this. Limited information is available regarding the susceptibility of wildlife to 
M. orygis infection and disease. 
 
5. Diagnostic tools for TB in wildlife in SA 
The validation of diagnostic tests for wildlife is limited by the access to and number of high-
quality samples from confirmed infected and uninfected species (Chileshe et al., 2019). Due 
to logistical challenges, it can be difficult to confirm MTBC infection, especially from 
suspected cases using ante mortem samples. In this section, we review recent advances in 
techniques for detecting MTBC infection in wildlife in SA. 
 
5.1. Mycobacterial culture  
In recent years, there have been advances in techniques for improving direct detection of 
MTBC organisms; however, most techniques still require growing the organism to detectable 
levels using different mycobacterial culture techniques. Due to the inherent slow growth of 
mycobacteria, the development of improved culture techniques using special media was 
initiated. The BACTEC™ MGIT™ (Becton Dickinson, Franklin Lakes, NJ, USA) is an 
automated mycobacterial growth detection system that has been used to culture MTBC 
organisms from post mortem tissue samples as well as ante mortem bronchoalveolar lavage 
(BAL), trunk wash fluid and oropharyngeal swab samples from wildlife. Application of these 
techniques has permitted ante mortem diagnosis of M. bovis infection in lion, wild dog and 





TiKa (TiKa Diagnostics, UK) is a novel specialised culture medium, used together with the 
BACTEC™ MGIT™ system, with the unique ability to stimulate MTBC growth, and 
improve sensitivity (Se) of mycobacterial culture, even from samples with low bacterial loads 
or high dilution. TiKa increases mycobacterial recoverability, improves the Se of detection 
and decreases the time required to determine a result compared to standard culture methods 
(Bull et al., 2017). A pilot study has shown TiKa improves MTBC growth and time to a 
positive result in a number of wildlife species including buffaloes, elephants and rhinoceroses 
(Goosen, unpubl. data). 
  
5.2. Direct detection 
Various polymerase chain reaction (PCR)-based methods have been developed and adapted 
to identify specific MTBC organisms, based on detecting the presence of mycobacterial 
DNA, from either cultured clinical samples or directly from clinical samples (Michel et al., 
2009; Goosen, unpubl. data). Three of the most common molecular typing tools used to 
genetically differentiate MTBC members are: i) spacer oligonucleotide typing 
(spoligotyping), ii) variable number of tandem repeats (VNTR) typing of mycobacterial 
interspersed repetitive units (MIRU), and iii) region of difference (RD) analysis (Kamerbeek 
et al., 1997; Brudey et al., 2004; Supply et al., 2006; Warren et al., 2006). Spoligotyping is 
most commonly used to detect and genotype the MTBC isolates to determine the 
phylogenetic relationships to organisms from specific geographical regions and sources 
(Table 2.3). Next generation sequencing (NGS) is a novel tool with increased resolution and 
discriminatory power compared to the other three genotyping methods. The generation of 
whole genome sequences (WGS) allows distinct genetic profiles to be identified at a 
nucleotide level, and MTBC molecular epidemiology and genetic diversity can be 





differentiation of MTBC isolates unable to be differentiated using spoligotyping (Roos, 
2018). Therefore, increased application of WGS will improve molecular epidemiology of TB 
outbreaks in wildlife and at interfaces. 
 
Table 2.3 The SB numbers of Mycobacterium bovis isolates identified in free-ranging wildlife 
species in South Africa as determined by spoligotyping, by the location of the infected species 
and including references. 
SB # KNPa GKNPb HiPc KZNd MGRe References 
SB0120 - √ - - - Hlokwe et al., 2014; Roos, 2018 
SB0121 √ √ √ √ - Hlokwe et al., 2011; Dippenaar et al., 2017 
Miller et al., 2018a; Roos, 2018 
SB0130 - √ √ √ √ Hlokwe et al., 2011, 2014; Michel et al., 2009; 
Dippenaar et al., 2017 
SB0140 - - √ √ √ Hlokwe et al., 2016; Dippenaar et al., 2017  
SB1275 - √ - -  Roos, 2018 
SB1388 - √ - - - Roos, 2018 
SB1474 - - √ √ - Hlokwe et al., 2011 
SB2200 - √ - - - Hlokwe et al., 2014 
SB0294 - √ - - - Hlokwe et al., 2019 
a Greater Kruger National Park 
b Kruger National Park 
c Hluhluwe iMfolozi Park 
d KwaZulu-Natal 
e Madikwe Game Reserve 
 
Automation of PCR-based methods allows procedures to be simplified, standardised and is 
useful for high throughput data. The GeneXpert® (Cephied, Sunnyvale, CA, USA) is a 





designed to diagnose Mtb infection in humans via PCR. It is a rapid, simple-to-use, 
automated platform that is being optimised to detect Mtb and M. bovis from wildlife samples 
including homogenised post mortem tissue samples and ante mortem BAL fluids and swabs 
(Goosen, unpubl. data).  
 
5.3. Indirect detection  
Despite improvements in identifying MTBC directly, detection of host immune responses 
remains the principal method used to diagnose infection in wildlife. Indirect methods rely on 
measuring the anamnestic cell-mediated or humoral immune responses to MTBC antigens in 
host species (Table 2.4). The presentation of clinical disease may also be used as an indirect 
method of detecting TB but this is insensitive as clinical disease is typically only observed in 
advanced stages (Renwick et al., 2007). 
 
5.3.1. Cell-mediated immunity 
The detection of cell-mediated immune responses relies on stimulating a memory response, 
in vivo or in vitro, with MTBC antigens and then quantifying that response as a delayed-type 
hypersensitivity reaction or production of cytokine biomarkers of immune activation, 
respectively. The development of specific stimulating antigens instead of tuberculin, which 
varies according to batches and sources (Monaghan et al., 1994), has improved the detection 
of cell-mediated immune responses to MTBC organisms (Goosen et al., 2014). The 
QuantiFERON® TB-Gold (QFT) system is an easy-to-use stimulation platform, with 
standardised antigenic peptides and controls, which when used with specific cytokine 
enzyme-linked immunosorbent assays (ELISAs), can detect Mtb and M. bovis infection in a 
number of wildlife species (Parsons et al., 2009; Olivier et al., 2017; Higgitt et al., 2017, 





changing gene expression pattern reflects a biological response, has shown utility in the 
diagnosis of M. bovis infection in lions and buffaloes by measuring the expression of CXCL9 
mRNA and interferon gamma (IFN-γ) mRNA, respectively (Parsons et al., 2012; Olivier et 
al., 2017). Furthermore, GEA has been used to detect immune sensitization to M. bovis in 
spotted hyena, measuring the expression of CXCL9 and CXCL11 mRNA (Higgitt et al., 
2017). 
 
The cytokine IFN-γ is the most commonly used biomarker to quantify in vitro cell-mediated 
immune responses in wildlife. Commercially available ELISAs have been evaluated and 
optimised to detect cytokine production in specific wildlife species; the ruminant cattletype® 
IFN-gamma ELISA (Qiagen, Venlo, Limburg, Netherlands) detects buffalo IFN-γ (Bernitz et 
al., 2018), the Quantikine canine IFN-γ ELISA (R&D Systems, Inc., MN, USA) detects wild 
dog IFN-γ (Higgitt et al., 2017) and the equine IFN-γ ELISAPRO (Mabtech, Nacka Strand, 
Sweden) detects white rhinoceros IFN-γ (Chileshe et al., 2019). Moreover, alternative 
biomarkers to IFN-γ have been investigated with the chemokine IFN-γ-inducible protein-10 
(IP-10), which has been shown to be a sensitive biomarker of immune activation in buffalo, 
meerkats and warthogs (Clarke et al., 2016b; Roos et al., 2018; Bernitz et al., 2019). 
Additionally, the parallel measurement of IFN-γ and IP-10 has been shown to maximise the 
detection of M. bovis-infected buffaloes while maintaining specificity (Sp) (Bernitz et al., 
2019).  
 
5.3.2. Humoral immunity 
Serological assays have also been used to detect infection by MTBC organisms in multiple 





Table 2.4 Indirect diagnostic tools to detect infection with members of the Mycobacterium tuberculosis complex in free-ranging wildlife species 
in South Africa. 
Species TST/SCITTa IGRAb CRAc Serology GEAd References  
Syncerus caffer √ √ √ √ √ Jolles et al., 2005; Parsons et al., 2012; van der Heijden et al., 2016; Bernitz et al., 2019 
Papio ursinus √ √ - - - Keet et al., 2000; Parsons et al., 2009  
Panthera leo √ √ - √ √ Keet et al., 2010; Miller et al., 2012; Olivier et al., 2017; Viljoen et al., 2018 
Panthera pardus √ - - - - Kerr unpubl. data 
Crocuta crocuta - - - - √ Higgitt et al., 2017 
Acinonyx jubatus √ - - √ √ Kerr unpubl. data 
Lycaon pictus √ √ - √ - Higgitt et al., 2018 
Phacochoerus aethiopicus √ - √ √ - Roos et al., 2016, 2018 
Ceratotherium simum - √ - - - Chileshe et al., 2019 
Diceros bicornis - √ - √ - Morar et al., 2013; Miller et al., 2015b  
Loxodonta africana - √ - √ - Kerr et al., 2019 
Suricata suricattae - - √ √ - Drewe et al., 2009; Clarke et al., 2016b 
a tuberculin skin test/single comparative intradermal tuberculin test 
b interferon gamma release assay 
c cytokine release assay 





assays as whole blood stimulation is not required. However, CMI-based assays have 
shown greater Se in many species (Maas et al., 2013) and detect mycobacterial 
infections earlier than serological assays, as the humoral immune response requires 
the in vivo production of antibodies, which may only occur later in infection. 
Circulating antibodies can be detected via ELISA as demonstrated in warthogs where 
an indirect in-house purified protein derivative (PPD) ELISA and the TB ELISA-VK® 
kit (Vacunek, Bizkaia, Spain) were able to differentiate between M. bovis culture-
positive and negative animals (Roos et al., 2016). Alternatively, circulating antibodies 
can be detected using rapid cartridge-based systems. The Dual Path Platform Vet TB 
Assay (DPP® VetTB) for Cervids® (Chembio Diagnostic Systems, Inc., Medford, 
New York, USA) has been used to diagnose M. bovis infection in warthogs (Roos et 
al., 2016) and the Elephant TB STAT-PAK® Assay (Chembio) and the DPP® VetTB 
for Elephants (Chembio) was used to determine the seroprevalence of M. bovis 
infection in elephants in KNP (Kerr et al., 2019). The development and optimisation 
of diagnostic tools to identify MTBC infection is the gateway to identify affected 
species or individuals to manage transmission and disease. 
 
6. Discussion  
Multi-host pathogen systems are intrinsically complex and an ecosystem level 
approach to effective disease management is required. Mycobacterium bovis and Mtb 
are multi-host pathogens and thus, the population dynamics of each host species and 
multidirectional transmission at interfaces makes control difficult. The epidemiology 
of the pathogen in each host needs to be understood at an individual and population 
level as information from one species cannot be easily extrapolated to the next 





susceptibility, disease progression and transmission. This may define the role of the 
host in the ecosystem, i.e. a maintenance or dead-end. Lions become infected with M. 
bovis via ingesting infected meat and this may cause generalised disease. Systemic 
infection results in relatively rapid mortality in lions (Keet et al., 1996) and for this 
reason, lions are considered dead-end hosts. Alternatively, buffaloes become infected 
via inhalation of aerosolised bacteria and this causes localised disease in the lungs and 
lymph nodes (Michel et al., 2007). Morbidity and mortality due to M. bovis infection 
may take months or years, so infected buffaloes are constant sources of infection and 
for this reason are considered maintenance hosts. Moreover, an array of factors such 
as environmental conditions, like droughts, may impact the risk and outcome of 
infection. 
 
Experimental infection of wildlife is not always be possible, but allows an in-depth 
understanding of the infection, immune responses, pathological changes, clinical 
signs and transmission of wildlife TB (Michel et al., 2017). Moreover, a powerful tool 
to perform in depth epidemiological analyses is NGS. In New Zealand, NGS was used 
to investigate transmission of M. bovis between cattle and brushtail possums 
(Trichosurus vulpecula) with the possibility of incorporating this method of typing 
into routine testing programmes (Crispell et al., 2017). As the cost of NGS decreases 
and accessibility increases, this method may become the standard tool for 
investigating TB outbreaks. Moreover, NGS can be used to determine if the 
reoccurrence of bTB in populations is residual infection or reintroduction, which 
improves the understanding of the infection risks, transmission and maintenance hosts 






The increase in geographical distribution of TB in SA highlights the need to identify 
infected species by enforcing testing and preventing the movement of test-positive 
animals (Hlokwe et al., 2014). The human/wildlife/livestock interface is increasing 
with highly fragmented conservation areas being encroached upon by humans 
(Davies-Mostert et al., 2015; Hunter, 2018). Moreover, poorly maintained biosecurity 
(fences) within SA, and between SA and bordering countries, increase the risk of 
geographical spread of TB (Hlokwe et al., 2014). However, physical barriers such as 
biosecurity measures may not be effective in containing warthogs or kudus, which are 
two potential maintenance hosts of M. bovis in SA (Keet et al., 2001; Roos et al., 
2018).  
 
In SA over the past decade, MTBC members have been discovered in new wildlife 
species. It is unknown whether this is due to an advancement in diagnostic tools, 
increased inter-species transmission, or a combination of both (Hlokwe et al., 2014). 
Moreover, the true prevalence and incidence of wildlife TB is unknown, even though 
this is important for understanding the epidemiology and management of this disease. 
Neglecting subclinical infections may lead to misleading conclusions regarding the 
source, maintenance, and transmission of TB within or between populations.  
 
Current tests to detect TB infection in wildlife usually require animals to be captured 
and chemically immobilised. In addition to the cost and logistical issues, the 
intermittent availability of tuberculin and immobilisation drugs in SA can limit 
testing. The development of tools with improved performance that require non-
invasive sampling methods, such as faecal sampling, would greatly improve screening 





of bTB control, such as test-and-cull programmes, cannot be ethically implemented, 
although may be a regulatory requirement. To increase the detection of infected 
species in SA, surveillance needs to be increased, which is currently limited by the 
diagnostic tools available. A pilot surveillance project in KNP, using retrospective 
serological testing (DPP® VetTB) and prospective culture of BAL samples, has been 
implemented to detect M. bovis and Mtb infection in elephants to assess the potential 
risk in this species (Miller et al., 2019). However, there are other opportunities for 
surveillance, including examination of hunted animals, those found dead due to 
poaching or other events, animals culled for population management, during 
immobilization for movement, and at the abattoir (Miller et al., 2017a). These may be 
less costly and provide a broader sampling of animals to increase surveillance.  
 
Although the need for control of TB in wildlife in SA is recognised, similar to many 
developing countries worldwide, limited resources confound control measures. 
Wildlife TB threatens management and conservation efforts to protect wildlife and 
joint cooperation by government, communal and commercial farmers, conservation 
organizations, veterinarians and industry is required to effectively control the disease. 
The conservation of all susceptible species relies on accurate tools to identify and 
remove infected animals from the population or limit the movement of infected 
animals to areas that remain uninfected.  
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African buffaloes (Syncerus caffer) are wildlife maintenance hosts of Mycobacterium 
bovis, the cause of bovine tuberculosis. Consequently, M. bovis-infected buffaloes 
pose a transmission risk for cattle and other wildlife species. Previously, a 
modification to the Qiagen QuantiFERON®-TB Gold (QFT) system, using QFT tubes 
and an in-house bovine interferon-gamma (IFN-γ) ELISA, was evaluated for the 
detection of M. bovis infection in buffaloes. Subsequently, Qiagen has developed a 
commercially available cattletype® IFN-gamma ELISA for the detection of antigen-
specific IFN-γ release in ruminants. The aim of this study was to investigate the use 
of QFT tubes and the cattletype® IFN-gamma ELISA, in a QFT IFN-γ release assay 
(IGRA), to detect M. bovis infection in African buffaloes. The test agreements 
between the QFT IGRA, single comparative intradermal skin test (SCITT) and 
Bovigam® IGRA in two M. bovis-exposed buffalo populations (n = 134 and n = 92) 
were calculated and κ coefficients ranged from 0.65 (95% CI 0.48-0.82%) to 0.86 
(95% CI 0.72-0.99%). Increasing the QFT incubation time in one M. bovis-exposed 
buffalo cohort (n = 92), from 20 to 40 h, had no effect on the QFT IGRA test results. 
Inter-assay and intra-assay reproducibility determination for the QFT IGRA produced 
coefficient of variations (CV) < 9.1% and < 1.7%, respectively. A total of 21/21 
known M. bovis-unexposed buffaloes tested QFT IGRA-negative. Moreover, the QFT 
IGRA test result values were significantly greater for 13 M. bovis culture-positive 
buffaloes compared with 14 M. bovis-exposed culture-negative (p < 0.01) and 21 M. 
bovis-unexposed (p < 0.001) buffaloes, respectively. These findings suggest that the 
combination of QFT tubes and the cattletype® IFN-gamma ELISA is a promising new 





However, further research is needed to evaluate the sensitivity and specificity of the 






1. Introduction  
Mycobacterium bovis (M. bovis) infection causes bovine tuberculosis (bTB), a 
zoonotic disease affecting a broad range of hosts (Michel et al., 2006). Two of South 
Africa's (SA) largest wildlife reserves, the Kruger National Park (KNP) and Hluhluwe 
iMfolozi Park (HiP), are endemic for M. bovis. Within these reserves, African 
buffaloes (Syncerus caffer) are one of the most important maintenance hosts of M. 
bovis (de Vos et al., 2001). More recently, buffaloes in smaller reserves like Madikwe 
Game Reserve (MGR) and privately-owned farms in SA have been diagnosed with 
bTB (Hlokwe et al., 2016). M. bovis-infected buffaloes do not only pose a 
transmission risk to other wildlife species, particularly large carnivores such as 
African lions (Panthera leo) (Olivier et al., 2017), but also to economically important 
livestock such as domestic cattle populations (de Vos et al., 2001; Musoke et al., 
2015). Early detection of M. bovis infection in buffaloes is necessary to reduce the 
risk of transmission to other animals. Furthermore, prompt identification of these 
animals will reduce the risk of infection in buffaloes through translocation and 
improve the success of disease management strategies. 
 
The early diagnosis of M. bovis infection relies primarily on the measurement of 
pathogen-specific cell-mediated immune responses (Vordermeier et al., 2000). In 
South Africa, the only such test approved for buffaloes is the single comparative 
intradermal tuberculin test (SCITT) that detects a delayed-type hypersensitivity 
response to M. bovis purified protein derivative (PPDb). However, this test has 
numerous drawbacks: i) the use of PPDb, a cocktail of M. bovis antigens, may result 
in cross-reactive immune responses to other non-virulent mycobacteria (Michel, 





(Coad et al., 2010) and iii) the interpretation of the SCITT response can be subjective 
and may vary between operators (Pers. Comm. A McCall). Furthermore, 
administering and reading the test in wildlife poses logistical challenges as animals 
need to be confined for three days and immobilised twice during this period. 
 
An alternative test, the interferon-gamma (IFN-γ) release assay (IGRA) is an in vitro 
whole blood assay that is more suitable than the SCITT for use in wildlife since it 
only requires the collection of a single blood sample (Grobler et al., 2002). The 
Bovigam® IGRA, utilizing both PPDb and Mycobacterium avium PPD (PPDa) as 
stimulating antigens, is a commercially available IGRA used for the diagnosis of M. 
bovis infection in domestic cattle (de la Rua-Domenech et al., 2006) and has shown 
great promise for use in buffaloes (Grobler et al., 2002). The inclusion of PPDs as 
antigens in this IGRA, as for the SCITT, may also result in a cross-reactive immune 
response to non-virulent mycobacteria; however, the specificity (Sp) of IGRAs can be 
improved by using specific mycobacterial peptides as stimulating antigens 
(Vordermeier et al., 2001; Bass et al., 2013).  
 
The test performance of a modified QuantiFERON®-TB Gold (QFT) assay (mQFT), 
using commercially available QFT tubes and an in-house bovine-specific IFN-γ 
ELISA, has previously been reported for African buffaloes (Parsons et al., 2011). The 
QFT system uses three specific antigenic peptides, early secretory antigen target 6 kD 
(ESAT-6), culture filtrate protein 10 kD (CFP-10) and TB7.7(p4), encoded in the 
region of difference one (RD1) that is not present in most nontuberculous 
mycobacteria and M. bovis Bacille Calmette-Guèrin (Vordermeier et al., 2001, 





of the mQFT to be comparable to that of the SCITT. Additionally, the relative Se of 
the mQFT could be improved by increasing the whole blood antigen incubation time 
(Goosen et al., 2014).  
 
Qiagen has developed a new commercially available cattletype® IFN-gamma ELISA, 
suitable to detect antigen-induced IFN-γ release, with a specified cutoff for 
determining positive and negative responses. In this study, we aimed to investigate 
the use of QFT tubes in conjunction with the cattletype® IFN-gamma ELISA in a 
novel IGRA. We aimed to: i) compare the performance of the QFT IGRA with the 
SCITT and Bovigam® IGRA; ii) investigate the effect of increased duration of blood 
incubation on the assay result; iii) determine the reproducibility of the assay and iv) 
evaluate the assay in M. bovis-unexposed buffaloes. 
 
2. Materials and methods 
2.1. M. bovis-exposed buffaloes in HiP  
During July 2016, 403 randomly selected free-ranging buffaloes were mass captured 
during the park’s 18th annual bTB test-and-cull programme. All buffaloes were 
immobilised, lithium heparin whole blood was collected via jugular venipuncture and 
the SCITT were performed as described below. All suspect and positive SCITT 
buffaloes (n = 22) were culled by gunshot. In addition to the 22 buffaloes, an 
additional five SCITT-negative buffaloes were culled based on suspicion of bTB. Of 
all the SCITT-negative buffaloes (n = 381), 70 animals were randomly selected and 







2.2. M. bovis-exposed buffaloes in MGR 
One-hundred and thirty-four buffaloes were opportunistically sampled from the MGR 
during bTB prevalence testing from May to July 2016. Free-ranging buffaloes were 
individually captured in MGR and immobilised, after which lithium heparin whole 
blood was collected via jugular venipuncture and SCITTs performed as described 
below. Bovigam® IGRAs were performed at the Tuberculosis Laboratory of the 
Agricultural Research Council (ARC)-Onderstepoort Veterinary Institute in Pretoria, 
South Africa as described previously (van der Heijden et al., 2017). All suspect and 
positive SCITT buffaloes and positive Bovigam® IGRA buffaloes (n = 34) were 
culled by gunshot. All buffaloes sampled (n = 134) were used in this study. 
 
2.3. M. bovis-unexposed and uninfected buffaloes 
Twenty-one buffaloes were opportunistically sampled from M. bovis-free farms 




All SCITTs were performed in HiP and MGR as previously described (Parsons et al., 
2011). Briefly, an area on either side of the buffalo’s neck was shaved and the 
baseline skin fold thickness (SFT) measured. Intradermal injections of 0.1 ml of PPDb 
(3000 IU) and 0.1 ml of PPDa (2500 IU) were administered on the left and right side 
of the animal’s neck, respectively. After three days, buffaloes were immobilised and 
their SFT measured. A differential SFT measurement of ≥ 2 mm between the PPDb 
injection site compared with the PPDa injection site was defined as SCITT-positive. 





reactions of between 0 and 2 mm as SCITT-suspect (Parsons et al., 2011). 
 
2.5. Bovigam® IGRA in HiP 
Whole blood aliquots (250 µl) from all 403 buffaloes sampled were co-incubated with 
i) 25 µl phosphate buffered saline (Nil) ii) 25 µl PPDa (2750 IU/ml) (Onderstepoort 
Biological Products, Pretoria, South Africa) iii) 25 µl PPDb (3300 IU/ml) 
(Onderstepoort Biological Products) and iv) 25 µl pokeweed mitogen (PWM), 5 
µg/ml final concentration (Sigma-Aldrich, St. Louis, MO, USA) in 2 ml safe-cap 
microcentrifuge tubes. All samples were inverted three times, incubated at 37 °C for 
20 h, centrifuged at 2550 x g for 10 min after which the plasma fraction was harvested 
and stored at -4 °C for later detection of IFN-γ using the Bovigam® ELISA (Prionics 
AG, Schlieren-Zurich, Switzerland) per manufacturer’s protocols. Due to the 
unavailability of Bovigam® ELISA plates at the time of testing in HiP, the Bovigam® 
ELISA was conducted retrospectively on samples from selected animals. 
 
2.6. QFT IGRA  
For all HiP (n = 403) and MGR (n = 134) buffaloes, 1 ml aliquots of heparinised 
whole blood were transferred to QFT tubes (Qiagen, Venlo, Limburg, Netherlands) 
comprising of: i) Nil tube containing saline; ii) TB antigen tube containing antigenic 
peptides and iii) mitogen tube, as previously described (Parsons et al., 2011). All 
tubes were inverted ten times and incubated at 37 °C for 20 h. For samples collected 
in MGR, the plasma fraction was harvested following centrifugation at 3000 × g for 
10 min. For samples collected in HiP, 150 µl of plasma was harvested from the tubes 
and these were incubated for an additional 20 h. The remaining plasma was then 





manufacturer’s protocols using all plasma samples harvested after 20 h and plasma 
harvested from the Nil and TB antigen tubes after 40 h from the HiP buffaloes. 
Results are presented as sample to positive ratio (S/P): (OD of QFT TB antigen – OD 
of QFT Nil)/ (OD cattletype® IFN-gamma ELISA positive control – OD cattletype® 
IFN-gamma ELISA negative control) x 100 as per manufacturer’s protocol. A 
positive test result was defined as: S/P ≥ 35%.  
 
2.7. Reproducibility of the QFT IGRA  
Heparinised whole blood was collected post-SCITT from two QFT IGRA/SCITT-
positive animals and one QFT IGRA/SCITT-negative animal. For each animal, blood 
was incubated at 37 °C for 20 h in three separate sets of QFT Nil and TB antigen 
tubes, and one QFT Mitogen tube. Plasma was harvested following centrifugation and 
three separate cattletype® IFN-gamma ELISAs were performed on the same day using 
the replicate samples.  
 
2.8. Post mortem examination and mycobacterial culture 
Post mortem examinations were performed on all culled buffaloes from HiP (n = 22). 
All lymph nodes, lungs and bTB-like lesions were sampled carefully for 
mycobacterial culture. All culture-positive samples were genetically speciated to 
confirm M. bovis infection (Warren et al., 2006). Mycobacterial culture and genetic 
speciation were performed at Stellenbosch University as previously described 
(Goosen et al., 2014). Samples collected during post mortems in MGR were not 







2.9. Data analyses  
Test agreements between the QFT IGRA, SCITT and Bovigam® IGRA were 
calculated as Cohen’s κ coefficient using the agreement calculator on the GraphPad 
Software website (http://graphpad.com/quickcalcs/kappa1/). The coefficient of 
variation (CV) for each stimulation condition, was calculated to determine the inter- 
and intra-assay reproducibility of the QFT IGRA. Test results for 21 M. bovis-
unexposed buffaloes were compared with 14 M. bovis-exposed culture-negative and 
13 M. bovis culture-positive buffaloes, using the Kruskal-Wallis H test with a Dunn's 
Multiple Comparison Test [H (2); p < 0.05] available on the GraphPad Prism version 
5 software (GraphPad Software Inc., San Diego, CA, USA).  
 
3. Results 
In HiP, 9/92 (16%), 19/92 (20%) and 20/92 (21%) buffaloes were QFT IGRA, SCITT 
and Bovigam® test-positive, respectively and in MGR, 24/134 (18%), 30/134 (22%) 
and 22/134 (16.5%) of buffaloes were test-positive for the aforementioned tests, 
respectively. All 21 M. bovis-unexposed buffaloes were QFT IGRA test-negative. 
 
In the combined M. bovis-exposed populations (n = 226), test agreements between the 
QFT IGRA and SCITT, and the two IGRAs had κ coefficients of 0.69 and greater 
(Table 3.1). In HiP, test agreement between the QFT IGRA and SCITT was 
calculated as κ = 0.86 (95% CI 0.72-0.99%); test agreement between the two IGRAs 
was calculated as κ = 0.75 (95% CI 0.58-0.93%) (Table 3.2). Similar test agreements 
were observed in MGR; agreement between the QFT IGRA and SCITT was 
calculated as κ = 0.72 (95% CI 0.58-0.87%), and agreement between the two IGRAs 





Table 3.1 Cohen’s kappa coefficient (κ) and 95% confidence interval estimates of 
agreement between the QFT IGRA, SCITT and Bovigam® IGRA for the detection of 
Mycobacterium bovis infection in African buffaloes in two M. bovis-exposed 
populations (n = 226). 
 QFT IGRA
a SCITTb Bovigam® IGRA 
QFT IGRA 1 0.78 (0.67-0.88) 0.69 (0.57-0.81) 
SCITT 0.78 (0.67-0.88) 1 0.70 (0.58-0.82) 
Bovigam® IGRA 0.69 (0.57-0.81) 0.70 (0.58-0.82) 1 
a interferon gamma release assay 
b single comparative intradermal tuberculin test 
 
Table 3.2 Cohen’s kappa coefficient (κ) and 95% confidence interval estimates of 
agreement between the QFT IGRA, SCITT and Bovigam® IGRA for the detection of 
Mycobacterium bovis infection in African buffaloes in Hluhluwe iMfolozi Park, South 
Africa (n = 92). 
  QFT IGRAa SCITTb Bovigam® IGRA 
QFT IGRA 1 0.86 (0.72-0.99) 0.75 (0.58-0.93) 
SCITT 0.86 (0.72-0.99) 1 0.77 (0.61-0.93) 
Bovigam® IGRA 0.75 (0.58-0.93) 0.77 (0.61-0.93) 1 
a interferon gamma release assay 








Table 3.3 Cohen’s kappa coefficient (κ) and 95% confidence interval estimates of 
agreement between the QFT IGRA, SCITT and Bovigam® IGRA for the detection of 
Mycobacterium bovis infection in African buffaloes from Madikwe Game Reserve, 
South Africa (n = 134). 
 
QFT IGRAa SCITTb Bovigam® IGRA 
QFT IGRA 1 0.72 (0.58-0.87) 0.65 (0.48-0.82) 
SCITT 0.72 (0.58-0.87) 1 0.65 (0.49-0.81) 
Bovigam® IGRA 0.65 (0.48-0.82) 0.65 (0.49-0.81) 1 
a interferon gamma release assay  
b single comparative intradermal tuberculin test 
 
The effect of lengthening the antigen incubation time of the QFT IGRA, from 20 to 
40 h, had no effect on the QFT IGRA test results in HiP (n = 92); the test results for 
all buffaloes that tested either positive or negative at 20 h remained the same at 40 h 
(data not shown). 
 
The two QFT IGRA-/SCITT-positive buffaloes selected for the reproducibility study 
were retrospectively confirmed to be Bovigam® IGRA-/M. bovis culture-positive and 
the one QFT IGRA-/SCITT-negative buffalo selected was confirmed to be Bovigam® 
IGRA-negative. For the QFT IGRA, the inter-assay (test variability) CVs were < 
9.1% and the intra-assay (test precision) CVs were < 1.7% (Tables 3.4 and 3.5). The 
S/P values remained unchanged for each replicate assay (data not shown).  
 
All M. bovis-unexposed buffaloes (n = 21) from historical M. bovis-free farms were 





Table 3.4 Inter-assay variability of the QFT IGRA to detect Mycobacterium bovis 
infection in African buffaloes as determined by the coefficient of variation (CV) using 






CV of means c (%) 
Positive #1d 
Nil 0.06 0.00 4.73 
TB antigen 2.24 0.17 7.48 
Positive #2d 
Nil 0.06 0.00 4.12 
TB antigen 2.14 0.15 6.81 
Negativee 
Nil 0.00 0.00 0.00 
TB antigen 0.06 0.01 9.08 
a mean of means of triplicates 
b standard deviation of means of triplicates 
c coefficient of variation of means of triplicates 
d QFT IGRA-/SCITT-/Bovigam® IGRA-/M. bovis culture-positive 
e QFT IGRA-/SCITT-/Bovigam® IGRA-negative 
 
The median S/P values of 13 M. bovis culture-positive buffaloes were significantly 
greater compared with the median S/P values of 21 M. bovis-unexposed (H = 28.5; p 
< 0.001) and 14 M. bovis-exposed culture-negative buffaloes (H = 15.9; p < 0.01) 
(Figure 3.1). The S/P values from the M. bovis-exposed culture-negative buffaloes 
were also significantly greater than the M. bovis-unexposed buffaloes (H = 12.62; p < 





buffaloes had S/P values < 35% and were therefore QFT IGRA test-negative (Figure 
3.1). 
 
Table 3.5 Intra-assay variability of the QFT IGRA to detect Mycobacterium bovis 
infection in African buffaloes as determined by the coefficient of variation (CV%) 
using buffaloes from Hluhluwe iMfolozi Park, South Africa. 
Buffalo Sample Meana SDb CVc (%) 
Positive #1d 
Nil 0.06 0.00 0.63 
TB antigen 2.04 0.02 1.20 
Positive #2d 
Nil 0.05 0.00 1.68 
TB antigen 2.02 0.01 0.64 
Negativee 
Nil 0.00 0.00 0.00 
TB antigen 0.06 0.00 1.63 
a mean of triplicates 
b standard deviation of triplicates 
c coefficient of variation of triplicates 
d QFT IGRA-/SCITT-/Bovigam® IGRA/M. bovis culture-positive 
e QFT IGRA-/SCITT-/Bovigam® IGRA-negative 
 
4. Discussion  
It has been previously reported that the Sp of IGRAs may be improved by using 
specific mycobacterial peptides (Parsons et al., 2011), with a possible decrease in Se 
(Goosen et al., 2014). In this study, we have shown the test performance of the QFT 





stimulating antigenic peptides and the commercially available ruminant-specific 
cattletype® IFN-gamma ELISA, to be similar to that of the currently available bovine-
specific assays that use PPDs in vivo (SCITT) or in vitro (Bovigam® IGRA) for the 
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Figure 3.1 QFT IGRA results (S/P values) for Mycobacterium bovis-unexposed 
buffaloes (n = 21), M. bovis-exposed culture-negative buffaloes (n = 14) and M. bovis 
culture-positive buffaloes (n = 13). The manufacturer’s prescribed cutoff for the 
cattletype® IFN-gamma ELISA is indicated by the dotted line (35%). Horizontal bars 
represent median and interquartile ranges. S/P values were significantly greater in 






Test agreements between the QFT IGRA and accepted diagnostic immunoassays for 
M. bovis detection in buffaloes were calculated. Test agreement between the QFT 
IGRA, SCITT and Bovigam® IGRA in both M. bovis-exposed buffalo populations 
had high κ coefficients, indicating concordance of results (McHugh, 2012) which 
supports the potential use of the QFT IGRA for the diagnosis of M. bovis infection in 
buffaloes. 
 
Our group previously demonstrated that the Se of the mQFT may be improved by 
increasing the whole blood incubation time albeit with a possible loss of Sp (Goosen 
et al., 2014). In the current study, we investigated whether an increased incubation 
time, from 20 to 40 h, would increase the detection of M. bovis-infected buffaloes by 
the QFT IGRA. Results demonstrated that although a lengthened incubation time did 
not detect additional QFT IGRA-positive animals, no additional Bovigam® IGRA or 
SCITT-negative buffaloes were test positive, suggesting no loss of Sp.  
 
The reproducibility of the QFT IGRA was confirmed by calculating the inter- and 
intra-assay variability. The acceptable CV percentage for inter- and intra-assay 
reproducibility is < 12% and 10%, respectively. The CV percentages from this study 
demonstrate the reproducibility of the QFT IGRA and supports the potential use of 
this assay as a diagnostic tool to detect M. bovis infection in buffaloes. The QFT 
IGRA test results (S/P values) remained unchanged across the replicates which further 
supports the reproducibility of this assay.  
 
The QFT IGRA was also tested using buffaloes from historical M. bovis-unexposed 





use of known M. bovis-unexposed buffalo herds to determine the Sp of an assay is a 
more reliable approach than using M. bovis-exposed culture-negative buffaloes. This 
is in part due to the high Se of current M. bovis assays and the fact that mycobacterial 
culture is regarded as an imperfect gold standard (de la Rua-Domenech et al., 2006). 
The QFT IGRA correctly classified all 21 M. bovis-unexposed buffaloes as test-
negative. 
 
Furthermore, our findings showed the median QFT IGRA S/P values to be 
significantly greater in M. bovis culture-positive buffaloes compared with M. bovis-
exposed culture-negative buffaloes and M. bovis-unexposed buffaloes, respectively, 
further demonstrating the potential diagnostic use of this IGRA (Figure 3.1). Median 
S/P values from M. bovis-exposed culture-negative buffaloes were significantly 
greater than M. bovis-unexposed buffaloes (Figure 3.1); although, it is known that 
culture is an imperfect gold standard. Therefore, the three M. bovis-exposed culture-
negative buffaloes with S/P values above 35% and positive QFT IGRA test results, 
may be truly infected.  
 
Furthermore, one culture-confirmed M. bovis-infected buffalo was QFT IGRA test-
negative with an S/P = 27%, just below the manufacturers prescribed cutoff of 35% 
(Figure 3.1). However, the QFT IGRA has not been validated for buffaloes and a 
species-specific cutoff may need to be calculated. As previously discussed, culture is 
an imperfect gold standard and therefore a buffalo-specific cutoff for the QFT IGRA 
may detect additional M. bovis-exposed culture-negative buffaloes that are truly 
infected. The advantage of a species-specific cutoff value to increase the Se of an 





can be standardised across several species with the only difference in the 
interpretation of the results using the specific cutoff. A larger sample size, where the 
infection status of all buffaloes is known, is required to confirm whether a species-
specific cutoff value or an increased antigen incubation time should be used to 
optimise the QFT IGRA to detect M. bovis infection in buffaloes.  
 
This study reports that the test performance of the QFT IGRA, using QFT tubes and 
the cattletype® IFN-gamma ELISA, is comparable to previously reported diagnostic 
assays for the detection of M. bovis infection in African buffaloes (Parsons et al., 
2011; Goosen et al., 2014; van der Heijden et al., 2016). Furthermore, we have shown 
that a lengthened antigen incubation time had no apparent effect on the QFT IGRA 
test results. The QFT IGRA was also shown to be highly reproducible and all M. 
bovis-unexposed buffaloes tested negative. Greater IFN-γ release was observed in M. 
bovis culture-positive compared with M. bovis-exposed culture-negative buffaloes, 
and measuring IFN-γ using the cattletype® IFN-gamma ELISA’s cutoff, we could 
distinguish between infected and uninfected buffaloes. In conclusion, this study 
suggests that the use of the QFT IGRA is a promising diagnostic test for the detection 
of M. bovis infection in African buffaloes. However, further research is warranted to 
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The diagnosis of Mycobacterium bovis (M. bovis) infection in African buffaloes 
(Syncerus caffer) relies on detection of the cell-mediated immune response to M. 
bovis antigens using the single comparative intradermal tuberculin test (SCITT) or 
interferon gamma release assays (IGRAs). The aim of the present study was to 
determine whether parallel testing with the SCITT and an IGRA increases the number 
of M. bovis-infected buffaloes detected by these assays. Culture-confirmed animals (n 
= 71) tested during routine bovine tuberculosis (bTB) control programmes in 
Hluhluwe iMfolozi Park and Madikwe Game Reserve in South Africa, were used in 
this study. Results from 35 buffaloes tested using the SCITT and three Bovigam® 
IGRAs (cohort A) and 36 buffaloes tested using the SCITT, Bovigam® IGRA and 
QuantiFERON®-TB Gold IGRA (cohort B) were analysed. The parallel use of the 
SCITT with selected IGRAs was able to identify all animals in both cohorts. These 
findings are in agreement with cattle studies supporting the use of the SCITT and 
IGRAs in parallel to identify the greatest number of M. bovis-infected animals. The 
suggested parallel testing algorithm should be strategically applied to maximise 







Mycobacterium bovis (M. bovis) infection causes bovine tuberculosis (bTB), a disease 
affecting a diverse range of hosts including domestic pets, livestock, wildlife and 
humans (Michel et al., 2006). African buffaloes (Syncerus caffer) are sylvatic 
reservoirs of M. bovis and spillover from buffaloes to wildlife, such as lions, and from 
buffaloes to livestock, such as cattle, has been demonstrated by molecular 
characterisation of mycobacterial strains (Hlokwe et al., 2014; Musoke et al., 2015). 
The first accounts of M. bovis infection in buffaloes in South Africa were documented 
in Hluhluwe iMfolozi Park (HiP) in 1986 (Jolles, 2004) and in Kruger National Park 
(KNP) in 1990 (Bengis et al., 1996). M. bovis infection has since been confirmed in 
numerous other wildlife species within these reserves, as well as more recently, in 
buffaloes in Madikwe Game Reserve (MGR) (Hlokwe et al., 2016) and privately-
owned farms in South Africa (SA).  
 
Bovine tuberculosis is a chronic disease and progression is characteristically slow. 
Current methods to detect M. bovis infection rely on tests quantifying cell-mediated 
immune responses to mycobacterial antigens (Vordermeier et al., 2000). Such tests 
include the single comparative intradermal tuberculin test (SCITT) and interferon 
gamma (IFN-γ) release assays (IGRAs). The SCITT detects a delayed-type 
hypersensitivity response to intradermal injection of purified protein derivative 
(PPD), namely Mycobacterium avium PPD (PPDa) and M. bovis PPD (PPDb). The 
SCITT is currently the only test approved for the diagnosis of bTB in buffaloes in SA 






The IGRA is an in vitro alternative to the SCITT and measures the release of IFN-γ in 
response to M. bovis antigens, using an enzyme-linked immunosorbent assay (ELISA) 
(Grobler et al., 2002). The Bovigam® IGRA is a commercially available test used for 
the diagnosis of bTB in cattle in which PPDs, like those used in the SCITT, are 
employed as stimulating antigens (de la Rua-Domenech et al., 2006). The use of a 
crude mix of mycobacterial antigens, such as PPD, has been shown to compromise 
IGRA specificity (Sp) in buffaloes (van der Heijden et al., 2016) and as a result, a 
second generation of IGRAs have been developed using specific peptides as 
stimulating antigens to improve Sp (Parsons et al., 2011). The Bovigam® peptide 
IGRAs, Bovigam® PC-EC and Bovigam® PC-HP IGRA, use early secretory antigen 
target 6 kD (ESAT-6) in combination with culture filtrate protein 10 kD (CFP-10), 
and Rv3615 in combination with three additional proprietary mycobacterial antigens, 
respectively, as stimulating antigens (Goosen et al., 2014). The QuantiFERON®-TB 
Gold (QFT) IGRA is a novel IGRA validated in buffaloes and makes use of the QFT 
tube stimulation system developed for humans containing ESAT-6 and CFP-10 
stimulating antigens (Bernitz et al., 2018). The Bovigam® peptide IGRAs and QFT 
IGRA have demonstrated high test-Sp in buffaloes (Goosen et al., 2014; Bernitz et al., 
2018). 
 
This study aimed to determine if parallel testing of buffaloes in high bTB prevalence 
herds, using the SCITT and IGRAs, namely the Bovigam®, Bovigam® PC-EC, 
Bovigam® PC-HP and QFT IGRA, increased the number of M. bovis-infected African 







2. Materials and methods 
2.1. Animals  
Buffalo populations in HiP and MGR were screened for M. bovis infection as part of 
bTB testing programmes. Buffaloes were immobilised for the SCITT and blood 
collection, as previously described (Parsons et al., 2011). Buffaloes that tested 
positive on one or more tests were culled for post mortem examination. Lymph nodes, 
lungs and bTB-like lesions were examined and sampled for mycobacterial culture as 
previously described (Goosen et al., 2014). Culture-positive samples were genetically 
speciated using polymerase chain reaction (PCR) to confirm M. bovis infection 
(Warren et al., 2006).  
 
Table 4.1 Tests performed in Hluhluwe iMfolozi Park in 2015, 2016 and 2017 and 
















2015 A (35) √ √  √ √ - 
2016 
B (36) 
√ √ - - √ 
2017 √ √ - - √ 
MGRd 2016 √ √ - - √ 
a single comparative intradermal tuberculin test 
b interferon gamma release assay  
c Hluhluwe iMfolozi Park 






During 2015, 283 HiP buffaloes were tested using the SCITT and three Bovigam® 
IGRAs. Of these, 63 buffaloes were culled and 35 were culture-confirmed to be 
infected with M. bovis (cohort A) (Table 4.1). During 2016 and 2017, a total of 688 
buffaloes from HiP and MGR were tested using the SCITT, Bovigam® and QFT 
IGRA. Of these, 94 were culled and 36 were culture-confirmed to be infected with M. 
bovis (cohort B) (Table 4.1). In total, 971 buffaloes were tested over a three-year 
period in HiP and MGR using the SCITT and a combination of IGRAs. Based on 
these results, 71 M. bovis culture-confirmed buffaloes were selected for inclusion in 
this study based on mycobacterial culture as the gold standard of M. bovis infection. 
 
2.2. Bovigam® IGRAs 
In HiP, the Bovigam® IGRA was performed in a temporary field laboratory as 
previously described (Bernitz et al., 2018). Briefly, aliquots of heparinised whole 
blood were incubated in microcentrifuge tubes with i) phosphate buffered saline, ii) 
2750 IU/ml PPDa (Onderstepoort Biological Products, South Africa), iii) 3300 IU/ml 
PPDb (Onderstepoort Biological Products), and iv) 5 µg/ml pokeweed mitogen 
(PWM) (Sigma-Aldrich, St. Louis, MO, USA). Samples were incubated at 37 °C for 
20 h, the plasma fraction harvested, IFN-γ measured using the Bovigam® ELISA and 
results interpreted per manufacturer’s instructions (Prionics AG, Schlieren-Zurich, 
Switzerland). The Bovigam® peptide IGRAs, i.e. Bovigam® PC-EC and Bovigam® 
PC-HP IGRAs, were performed as per the Bovigam® IGRA; however, 0.1 mg/ml PC-
EC and 0.1 mg/ml PC-HP peptide cocktails (Prionics AG) were used as stimulating 
antigens, respectively. For MGR buffaloes, the Bovigam® IGRA was performed at the 
Tuberculosis Laboratory of the Agricultural Research Council (ARC)-Onderstepoort 





Bovigam® protocol (van der Heijden et al., 2017). Aliquots of heparinised whole 
blood were incubated in 24-well cell-culture plates with i) 1000 IU/ml PPDa (Prionics 
AG), ii) 600 IU/ml PPDb (Prionics AG), and iii) 5 µg/ml pokeweed mitogen (PWM) 
(Sigma-Aldrich). Aliquots of blood with no added antigen served as unstimulated 
controls.  
  
2.3. QFT IGRA 
The QFT IGRA was performed as previously described (Bernitz et al., 2018). 
Aliquots of heparinised whole blood were aseptically transferred to tubes of the QFT 
system (Qiagen, Venlo, Limburg, Netherlands) and then incubated at 37 °C for 20 h. 
The plasma fraction was harvested following centrifugation and the cattletype® IFN-
gamma ELISA (Qiagen) was performed per manufacturer’s instructions.  
 
2.4. SCITT 
The SCITT was performed on all buffaloes as previously described (Parsons et al., 
2011). An area on either side of the buffalo’s neck was shaved and the skin fold 
thickness (SFT) measured. The SCITT was performed by injecting 2500 IU PPDa and 
3000 IU PPDb (Onderstepoort Biological Products) intradermally on either side of the 
buffalo’s neck. After three days, buffaloes were immobilised again and the SFT at 
each injection site was measured. Buffaloes were considered test positive if the 
increase in SFT at the PPDb site was 2 mm or greater than that at the PPDa site. 
 
2.5. Data analyses 
For each test and combinations of tests, the proportion of test-positive M. bovis-





values were calculated (http://www.socscistatistics.com/tests/ztest/Default.aspx). P-
values were considered statistically significant if p < 0.05. 
  
3. Results and Discussion 
In cohort A (n = 35), the Bovigam® PC-EC IGRA identified the fewest M. bovis-
infected buffaloes (28/35), the SCITT and Bovigam® PC-HP IGRA both identified 
30/35 buffaloes while the Bovigam® IGRA identified the greatest number (32/35). In 
cohort B (n = 36), the two IGRAs (Bovigam® and QFT IGRA) both identified 32/36 
M. bovis-infected buffaloes and the SCITT identified 33/36. No single test identified 
all M. bovis-infected buffaloes in either of the cohorts, in agreement with a previous 
study reporting imperfect sensitivity (Se) of the SCITT and IGRAs in cattle (de la 
Rua-Domenech et al., 2006). In contrast, parallel testing using the SCITT and an 
IGRA identified all infected animals; while no two blood-based assays, used in 
parallel, identified all infected buffaloes.  
 
In cohort A, the SCITT in combination with either of the Bovigam® peptide IGRAs 
identified all M. bovis-infected buffaloes (35/35) and were the only two-test 
combinations to achieve this in cohort A. Furthermore, using these tests in parallel 
identified a significantly greater number of infected buffaloes than were identified by 
any of the individual tests (p < 0.05) (Supplementary Table 4.1). The SCITT and 
Bovigam® IGRA in parallel identified 34/35 buffaloes. This proportion was not 
significantly different from the 35/35 buffaloes identified by the SCITT and either of 
the Bovigam® peptide IGRAs. The Bovigam® IGRA used in parallel with either of the 
Bovigam® peptide IGRAs identified 33/35 M. bovis-infected buffaloes while the 





cohort B, parallel testing using the two blood-based assays identified 35/36 infected 
buffaloes, while the SCITT and Bovigam® IGRA used in parallel identified all 
infected buffaloes (36/36), a significantly greater number than detected by the 

















































































































Figure 4.1 Thirty-five Mycobacterium bovis culture-confirmed buffaloes (Cohort A) 
were tested using four bovine tuberculosis tests [single comparative tuberculin skin 
test (SCITT), Bovigam® IGRA (PPD), Bovigam® PC-EC IGRA (EC) and Bovigam® 
PC-HP IGRA (HP)] singly and in combination. The number of test-positive buffaloes 
for each test and various combinations are shown. Statistical analyses were 




















































































Figure 4.2 Thirty-six Mycobacterium bovis culture-confirmed buffaloes (Cohort B) 
were tested using three bovine tuberculosis tests (single comparative tuberculin skin 
test (SCITT), Bovigam® IGRA (PPD) and QFT IGRA) singly and in combination. The 
number of test-positive buffaloes for each test and various combinations are shown. 
Statistical analyses were performed and represented in Supplementary Table 4.2. 
 
Results of the SCITT and Bovigam® IGRA performed on all 71 infected buffaloes 





Bovigam® IGRA identified 64/71 buffaloes. In parallel, the SCITT and Bovigam® 
IGRA identified all but one buffalo (70/71), a significantly greater number than 
identified by these tests individually (p < 0.05) (Figure 4.3). Other studies have shown 
that the SCITT and IGRAs identify different subsets of M. bovis-infected cattle 
(Vordermeier et al., 2006; Schiller et al., 2010) and consequently, when these tests are 
used in combination, a greater number of infected cattle are identified (Gonzàlez 
Llamazeres et al., 1990; Gormley et al., 2006). This is comparable to our findings that 
in parallel, the SCITT and an IGRA identified more infected buffaloes than these tests 
individually detected. Parallel testing using any two tests does not intrinsically 
increase Se since two tests with different performance characteristics are required to 
be performed in parallel to increase Se (Sheringham et al., 2015). For example, results 
from this study showed that the SCITT and QFT IGRA used in parallel detected the 
same number of buffaloes as the SCITT alone (cohort B). These two tests had high 
test agreement in a previous study (Bernitz et al., 2018), suggesting that they were 
detecting the same individual buffaloes. 
 
Bovine PPD has been shown to be a more sensitive stimulating antigen than specific 
peptides such as Bovigam® PC-EC and PC-HP antigens in buffalo cytokine release 
assays (Goosen et al., 2014; van der Heijden et al., 2017). This has been demonstrated 
for the SCITT and Bovigam® IGRA in cattle (Schiller et al., 2010) and buffaloes 
(Michel et al., 2011). Therefore, in order to maximise detection of all infected animals 
from a known M. bovis-infected buffalo herd, such as in HiP and MGR, tests using 
PPD should be utilised. In the present study, the Bovigam® IGRA, which uses PPDs, 
consistently demonstrated that in parallel with the SCITT, the greatest number of M. 





assays, has previously been advocated in cattle herds (Gormley et al., 2006; 
Vordermeier et al., 2006) and should be strategically applied when the goal of testing 
is to remove as many infected animals as possible. In herds where maximizing 
detection of all infected animals is the goal, then the expected decrease in Sp would 
be considered acceptable, especially in high prevalence herds. However, when testing 
herds with no-known history of M. bovis or extremely valuable animals, a different 



















































Figure 4.3 Seventy-one Mycobacterium bovis culture-confirmed buffaloes were tested 
using two bovine tuberculosis tests [single comparative tuberculin skin test (SCITT) 
and Bovigam® IGRA (PPD)] singly and in parallel. The number of test-positive 
buffaloes for each test and in combination is shown. Proportions were compared 





Due to the logistics and costs involved in performing the SCITT on wild animals such 
as buffaloes, an ideal parallel testing strategy would be based on blood-based assays 
with diagnostic performances comparable to or better than the SCITT in combination 
with an IGRA. However, results from this study demonstrated that parallel testing 
using two or three IGRAs did not identify as many M. bovis-infected buffaloes as the 
SCITT and an IGRA performed in parallel, although the Bovigam® and QFT IGRAs 
used in parallel identified all but one infected buffalo in cohort B. Therefore, these 
two IGRAs used in combination should be further investigated.  
 
In conclusion, parallel testing, using the SCITT and an IGRA, increases detection of 
M. bovis-infected buffaloes when compared to detection using single diagnostic tests. 
Additionally, since the SCITT identified additional M. bovis-infected buffaloes which 
were not detected using a single or combination of IGRAs, it is not currently possible 
to replace the SCITT in a testing algorithm that includes an IGRA without losing Se. 
However, since buffaloes were culled based on a positive test result, it is not known if 
there were any additional truly M. bovis-infected buffaloes that were negative on all 
tests in these populations. Furthermore, because mycobacterial culture is an imperfect 
gold standard (de la Rua-Domenech et al., 2006), buffaloes that were culture-
negative, but had evidence of M. bovis infection (based on immunological tests), were 
not included in our analysis. Additional strategies to develop a diagnostic algorithm 








Supplemental Table 4.1 A summary of the statistical scores from 35 Mycobacterium bovis culture-confirmed buffaloes tested in Hluhluwe 
iMfolozi Park in 2015, that were test-positive using the single comparative tuberculin skin test (SCITT) and Bovigam® IGRA (PPD), Bovigam® 
PC-EC IGRA (EC) and Bovigam® PC-HP IGRA (HP) singly and in combination (Table 4.1). Proportions were compared using a two-tailed z-
test. *p < 0.05 and **p < 0.01 and z scores are indicated in brackets. 
PPDa NSd - - - - - - - - - - - - - 
ECb NS NS - - - - - - - - - - - - 
HPc NS NS NS - - - - - - - - - - - 
SCITT, PPD NS NS *(2.2) NS - - - - - - - - - - 
SCITT, EC * (2.3) NS **(2.7) *(2.3) NS - - - - - - - - - 
SCITT, HP *(2.3) NS **(2.7) *(2.3) NS NS - - - - - - - - 
PPD, EC NS NS NS NS NS NS NS - - - - - - - 
PPD, HP NS NS NS NS NS NS NS NS - - - - - - 
EC, HP NS NS NS NS NS *(2.3) *(2.3) NS NS - - - - - 
SCITT, PPD, EC *(2.3) NS **(2.7) *(2.3) NS NS NS NS NS *(2.3) - - - - 
SCITT, PPD, HP *(2.3) NS **(2.7) *(2.3) NS NS NS NS NS *(2.3) NS - - - 
SCITT, EC, HP *(2.3) NS **(2.7) *(2.3) NS NS NS NS NS *(2.3) NS NS - - 
PPD, EC, HP NS NS NS NS NS NS NS NS NS NS NS NS NS - 
SCITT, PPD, EC, HP *(2.3) NS **(2.7) *(2.3) NS NS NS NS NS *(2.3) NS NS NS NS 
  SCITTe PPD EC HP SCITT, PPD SCITT, EC SCITT, HP PPD, EC PPD, HP EC, HP SCITT, PPD, EC SCITT, PPD, HP SCITT, EC, HP PPD, EC, HP 
a Bovigam® IGRA 
b Bovigam® PC-EC IGRA 
c Bovigam® PC-HP IGRA 
d not statistically significant 






Supplemental Table 4.2 A summary of the statistical scores from 36 Mycobacterium bovis culture-confirmed buffaloes tested in Hluhluwe 
iMfolozi Park in 2016 and 2017 and in Madikwe Game Reserve in 2016, that were test-positive using the single comparative tuberculin skin test 
(SCITT), Bovigam® IGRA (PPD) and QFT IGRA singly and in combination (Table 4.2). Proportions were compared using a two-tailed z-test. * 
p < 0.05 and z scores are indicated in brackets. 
PPDa NSc - - - - - 
QFT IGRAb NS NS - - - - 
SCITT, PPD NS *(2.0) *(2.0) - - - 
SCITT, QFT IGRA NS NS NS NS - - 
PPD, QFT IGRA NS NS NS NS NS - 
SCITT, PPD, QFT IGRA NS *(2.0) *(2.0) NS NS NS 
 SCITTd PPD QFT IGRA SCITT, PPD SCITT, QFT IGRA PPD, QFT IGRA 
a Bovigam® IGRA 
b QuantiFERON®-TB Gold IGRA 
c not statistically significant 
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The QuantiFERON®-TB Gold (QFT) stimulation platform for cytokine release is a novel 
approach for diagnosis of bovine tuberculosis in wildlife species. Plasma interferon gamma 
(IFN-γ) is routinely measured to detect immune sensitization to Mycobacterium bovis (M. 
bovis). However, the cytokine interferon gamma-inducible protein-10 (IP-10) has been 
proposed as an alternative, more sensitive, diagnostic biomarker. In this study, we 
investigated the use of the QFT system with measurement of IFN-γ and IP-10 in parallel to 
identify M. bovis-infected African buffaloes (Syncerus caffer). The test results of either 
biomarker in a cohort of M. bovis-unexposed buffaloes (n = 70) led to calculation of 100% 
test specificity. Furthermore, in cohorts of M. bovis culture-positive (n = 51) and M. bovis-
suspect (n = 22) buffaloes, the IP-10 test results were positive in a greater number of animals 
than the number based on the IFN-γ test results. Most notably, when the biomarkers were 
measured in parallel, the tests identified all M. bovis culture-positive buffaloes, a result 
neither the single comparative intradermal tuberculin test (SCITT) nor Bovigam® IFN-γ 
release assay (IGRA) achieved, individually or in parallel. These findings demonstrate the 
diagnostic potential of this blood-based assay to identify M. bovis-infected African buffaloes 
and a strategy to maximise the detection of infected animals while maintaining diagnostic 








Bovine tuberculosis (bTB) is an infectious zoonotic disease caused by Mycobacterium bovis 
(M. bovis). In South Africa (SA), the existence of wildlife maintenance hosts of M. bovis 
poses the biggest challenge in bTB eradication. African buffaloes (Syncerus caffer) are key 
M. bovis wildlife maintenance hosts and detection of infected buffaloes is vital to lower the 
transmission risk between wildlife species and domestic cattle (Musoke et al., 2015; Olivier 
et al., 2015). The identification of infected buffaloes will also prevent the translocation of 
these animals and thus limit the expansion of the disease’s geographic range (Grobler et al., 
2002). 
 
The diagnosis of bTB relies primarily on tests that quantify the cell-mediated immune 
response to M. bovis antigens (Vordermeier et al., 2000). In SA, the only ante mortem 
diagnostic test approved for the detection of M. bovis infection in African buffaloes is the 
single comparative intradermal tuberculin test (SCITT), using M. bovis purified protein 
derivative (PPD) (PPDb) and Mycobacterium avium PPD (PPDa). An in vitro alternative to 
the SCITT is the Bovigam® interferon gamma (IFN-γ) release assay (IGRA), a commercially 
available diagnostic test that was developed to detect M. bovis infection in cattle and may be 
less subject to operator bias and error than the SCITT (Wood and Jones, 2001). The 
Bovigam® IGRA is also used for bTB testing of buffaloes by measuring IFN-γ production in 
whole blood incubated in the presence of PPD (Grobler et al., 2002; van der Heijden et al., 
2016). The use of PPD may result in false-positive test results due to cross-reactive immune 
responses with non-tuberculous mycobacteria. 
 
The QuantiFERON®-TB Gold (QFT) IGRA is an assay using blood collection tubes 





(ESAT-6), culture filtrate protein 10 kD (CFP-10) and TB7.7(p4). The use of specific 
antigenic peptides has shown to increase the specificity (Sp) of IGRAs (Vordermeier et al., 
2001). Whole blood is incubated in the QFT tubes for 20-24 h, after which IFN-γ, released in 
response to the antigens, is measured in the plasma. Previous studies have demonstrated the 
utility of QFT tubes to stimulate antigen-specific IFN-γ responses in wildlife for detection of 
Mycobacterium tuberculosis (Mtb) infection in chacma baboons (Papio ursinus) (Parsons et 
al., 2009) and M. bovis infection in African buffaloes (Parsons et al., 2011; Bernitz et al., 
2018a). 
 
Assays using antigenic peptides are highly specific; however, this approach may compromise 
diagnostic sensitivity (Se) and thus additional biomarkers of immune activation have been 
identified. Interferon gamma-inducible protein-10 (IP-10), a cytokine produced at 
considerably higher levels than IFN-γ (Berry et al., 2010), has been proposed as a more 
sensitive diagnostic biomarker than IFN-γ for detecting host immune sensitization in humans, 
buffaloes and common warthogs (Phacochoerus africanus) (Ruhwald et al., 2009; Parsons et 
al., 2011; Roos et al., 2018). Preliminary work has shown that the QFT IP-10 release assay 
(QFT IPRA) has improved test Se compared to the QFT IGRA in buffaloes (Goosen et al., 
2015), however, no study has investigated the use the QFT IGRA and QFT IPRA in parallel 
to detect M. bovis-infected wildlife. 
 
The present study aimed to use the QFT stimulation platform in combination with both 
biomarkers IFN-γ and IP-10 to determine whether it can be used to maximise the detection of 
infected buffaloes, while maintaining test Sp and simplify bTB testing in field conditions. 
Furthermore, the study aimed to compare the detection of these assays with the SCITT and 





2. Materials and methods 
2.1. Buffalo cohorts 
Three buffalo cohorts were used for this study; 1) 70 M. bovis-unexposed; 2) 51 M. bovis 
culture-positive; and 3) 22 M. bovis-suspect animals. 
 
Cohort 1 consisted of buffaloes from M. bovis-free farms in SA with no known history of M. 
bovis-infection or bTB disease in any species. These M. bovis-unexposed buffaloes were used 
as uninfected controls. Between 2016 and 2018, whole blood was opportunistically collected 
from buffaloes when animals were immobilised for reasons unrelated to this study. The QFT 
IGRA and QFT IPRA were performed on all samples.  
 
Cohorts 2 and 3 consisted of buffaloes from M. bovis-endemic wildlife reserves in SA. In 
Madikwe Game Reserve in 2016 and Hluhluwe iMfolozi Park in 2016 and 2017, buffaloes 
were tested during bTB test-and-cull control programmes. Buffaloes were captured and 
immobilised to perform the SCITT, Bovigam® IGRA, QFT IGRA and QFT IPRA. No 
buffalo presented with any clinical signs of bTB disease, and only buffaloes that tested-
positive on one or more of the tests evaluated in this study were culled. Mycobacterial culture 
is the gold standard for M. bovis-infection and samples collected during post mortem 
examinations from each of the culled buffaloes underwent culture to confirm infection. 
Cohort 2 consisted of all mycobacterial culture-confirmed buffaloes detected during the three 
test-and-cull programmes. Of these 51 buffaloes, data from 36 animals had previously been 
reported (Bernitz et al., 2018b), while data from the remaining 15 buffaloes had not. Cohort 3 
consisted of buffaloes that were positive one or both of the PPD-based assays (SCITT and 
Bovigam® IGRA), but showed no bTB-like lesions upon post mortem examination and M. 





have a high probability of being infected with M. bovis. This is due to the Se of PPD and the 
fact that mycobacterial culture is an imperfect gold standard (de la Rua-Domenech et al., 
2006). These buffaloes were classified as M. bovis-suspect. 
 
2.2. SCITT and Bovigam® IGRA 
 The SCITT and Bovigam® IGRA were performed as previously described (Parsons et al., 
2011; Bernitz et al., 2018b). A positive SCITT result was defined as a differential skin fold 
thickness measurement of ≥ 2 mm between the PPDb injection site compared with the PPDa 
injection site. A positive Bovigam® IGRA result was defined as a differential OD value (450 
nm – 630 nm) of ≥ 0.1 between the PPDb stimulation compared with the unstimulated control 
in addition to an OD value of ≥ 0.1 between the PPDb stimulation compared with the PPDa 
stimulation.  
 
2.3. QFT IGRA 
The QFT IGRA was performed on all buffaloes as previously described (Bernitz et al., 
2018a). Briefly, aliquots of heparinised whole blood were aseptically transferred to blood 
collection tubes of the QFT system (Qiagen, Venlo, Limburg, Netherlands), i.e. an 
unstimulated control tube containing saline, an antigen tube containing ESAT-6, CFP-10 and 
TB-7.7(p4) peptides and a positive control tube (mitogen). Tubes were inverted ten times and 
incubated at 37 °C for 20 h. The plasma fraction was harvested following centrifugation and 
the Qiagen cattletype® IFN-gamma enzyme-linked immunosorbent assay (ELISA) was 
performed. Test results were interpreted per the manufacturer’s protocol and a QFT IGRA-







2.4. QFT IPRA 
Plasma harvested from QFT tubes was also assayed using an in-house bovine IP-10 ELISA 
(Kingfisher Biotech Inc., St Paul, MN, USA) as previously described (Parsons et al., 2016). 
The concentration of IP-10 in each sample was calculated using a standard curve generated 
from a dilution series of recombinant bovine IP-10 protein (Kingfisher Biotech Inc.). An 
assay result was defined as the concentration of IP-10 in the QFT Nil tube subtracted from 
the concentration of IP-10 in the QFT TB antigen tube, with a positive result being equal to 
or greater than 1486 pg/ml, based on a previously determined cutoff value (Goosen et al., 
2015). 
 
2.5. Data analyses 
The Sp of the QFT IGRA and QFT IPRA, individually and in parallel, were calculated as the 
percentage of M. bovis-unexposed buffaloes that were test-negative for each test, 
respectively. For both the M. bovis culture-positive and M. bovis-suspect cohorts, the 
proportion of buffaloes that were test-positive on the: i) SCITT; ii) Bovigam® IGRA; iii) 
QFT IGRA; iv) QFT IPRA; v) parallel interpretation of the PPD-based assays; and vi) 
parallel interpretation of the QFT assays, were compared using the exact binomial 
McNemar’s test with Bonferroni correction for multiple comparisons 
(http://scistatcalc.blogspot.com/2013/11/mcnemars-test-calculator.html). Results were 
considered statistically significant if p < 0.05/15 or p < 0.003. The QFT IGRA and QFT 
IPRA result values of M. bovis culture-positive buffaloes were compared to the QFT IGRA 
and QFT IPRA result values of M. bovis-suspect buffaloes, respectively, using the Kruskal-
Wallis H test with a Dunn's Multiple Comparison Test. Results were considered statistically 
significant if p < 0.05. All statistical tests were performed on GraphPad Prism version 5 






The QFT IGRA and QFT IPRA, individually and in parallel, classified all M. bovis-
unexposed buffaloes as test-negative (Table 5.1) and thus demonstrated 100% (95% CI 95-
100%) test Sp.  
 
Table 5.1 The number of buffaloes that tested positive and negative on all individual tests 
evaluated in this study and selected parallel interpretations of these tests, performed on three 
buffalo cohorts; i) Mycobacterium bovis-unexposed and uninfected; ii) M. bovis culture-
confirmed; and iii) M. bovis-suspect animals. Mycobacterial culture was used as the gold 
standard to confirm M. bovis infection in buffaloes. 
Test/s 
Uninfected (n = 70) Culture-positive (n = 51) Suspect (n = 22) 
Positive Negative Positive Negative Positive Negative 
SCITTa Not done 44 7 22 0 
Bovigamb Not done 41 10 11 11 
QFT IGRAc 0 70 41 10 7 15 
QFT IPRAd 0 70 45 6 18 4 
SCITT & Bovigam Not done 48 3 22 0 
QFT assayse 0 70 51 0 18 4 
a single comparative intradermal tuberculin test 
b Bovigam® interferon gamma release assay 
c QuantiFERON®-TB Gold interferon gamma release assay 
d QuantiFERON®-TB Gold interferon gamma-inducible protein-10 release assay 
e parallel interpretation of the QFT IGRA and QFT IPRA 
 
No individual test identified all M. bovis culture-confirmed buffaloes (Cohort 2); the 
Bovigam® IGRA and QFT IGRA individually identified 80% (95% CI 67-90%) of animals, 





(95% CI 76-96%) of animals (Table 5.1). Parallel interpretation of the SCITT and Bovigam® 
IGRA identified 94% (95% CI 84-99%) of M. bovis culture-positive buffaloes. Parallel 
interpretation of the QFT assays identified all [100% (95% CI 93-100%)] culture-positive 












































Figure 5.1 The magnitude of QuantiFERON®-TB Gold (QFT) interferon gamma release 
assay (IGRA) results (▼) and QFT interferon gamma-inducible protein-10 release assay 
(IPRA) results (●) for: i) Mycobacterium bovis-unexposed (n = 70); ii) M. bovis culture-
positive (n = 51) and iii) M. bovis-suspect (n = 22) buffaloes. The cutoff values for each 
assay are indicated by the dotted line. Horizontal bars represent median and interquartile 
ranges. Median QFT IGRA results in M. bovis culture-positive animals were significantly 







Median QFT IGRA result values for M. bovis culture-positive buffaloes were significantly 
greater compared with the median QFT IGRA result values for M. bovis-suspect buffaloes (p 
< 0.001). In contrast to this result, the median QFT IPRA result values of the two cohorts 
were not significantly different (Figure 5.1).  
 
All M. bovis-suspect buffaloes (Cohort 3) were SCITT-positive [100% (95% CI 85-100%)] 
and a subset of these were Bovigam® IGRA-positive [50% (95% CI 28-72%)] (Table 5.1). 
The QFT IPRA identified significantly more buffaloes [82% (95% CI 60-95%)] than the QFT 
IGRA [32% (95% CI 14-55%); p = 0.0009], but parallel interpretation of the QFT assays 
identified the same proportion of animals as the QFT IPRA alone (Table 5.1).  
 
4. Discussion 
In this study, measurement of both biomarkers IFN-γ and IP-10 in plasma harvested from the 
QFT stimulation system maximised the detection of M. bovis culture-confirmed buffaloes 
while maintaining test Sp.  
 
Both the QFT IGRA and IPRA demonstrated 100% Sp. This in agreement with a pilot study 
that estimated the QFT IGRA to be 100% specific in buffaloes (Bernitz et al., 2018a) and 
previous reports of improved Sp when M. bovis-peptides are used as stimulating antigens for 
IGRAs in cattle and buffaloes (Vordermeier et al., 2001; Buddle et al., 2003; Bass et al., 
2013; Goosen et al., 2014). Additionally, as for other species, the measurement of IP-10 in 
the QFT IPRA did not compromise the diagnostic Sp of the test (Ruhwald et al., 2011; 
Parsons et al., 2016). This characteristic is of particular importance in order to prevent 






The QFT IPRA identified a greater number of M. bovis culture-positive buffaloes and a 
significantly greater number of M. bovis-suspect buffaloes than the QFT IGRA. In 
agreement, studies measuring antigen-specific IP-10 have reported increased Se over IGRAs 
for diagnosing Mtb and M. bovis infection in humans and buffaloes, respectively (Ruhwald et 
al., 2009; Goosen et al., 2015). Notably, median QFT IGRA result values were significantly 
lower in the M. bovis-suspect cohort than the culture-positive cohort, suggesting that the 
suspect animals were at an early stage of infection, as it has been reported that antigen-
specific IFN-γ is a useful biomarker of disease severity (Vordermeier et al., 2002). In 
contrast, median QFT IPRA result values were similar in both groups, suggesting that this 
assay is not affected by disease status. We propose that not only is the measurement of IP-10 
in the QFT system more sensitive than IFN-γ, but IP-10 may also be a better biomarker of 
early infection. 
 
Both the SCITT and Bovigam® IGRA in parallel, and the QFT IGRA and IPRA in parallel, 
identified a greater number of M. bovis culture-positive buffaloes than did any individual 
assay. Similarly, previous studies have advocated the parallel use of the SCITT and 
Bovigam® IGRA to maximise the detection of M. bovis-infected cattle and buffaloes 
(Gormley et al., 2006; Bernitz et al., 2018b). Furthermore, the parallel measurement of IFN-γ 
and IP-10 has been reported to improve the Se of detecting Mtb and M. bovis infection in 
humans and cattle, respectively (Ruhwald et al., 2009; Coad et al., 2019). In our study, the 
parallel use of the QFT assays detected all of the M. bovis culture-confirmed buffaloes, and 
significantly more of the suspect animals than the QFT IGRA alone. Due to the high Se of the 
PPD assays together with mycobacterial culture as an imperfect gold standard, it was 
hypothesised that a proportion of the M. bovis-suspect buffaloes were truly infected, 





surprising that the QFT assays in parallel did not detect all animals in cohort 3, unlike the 
culture-confirmed group. However, in a control programme, detecting animals with early 
infection using the parallel QFT assays, although they may be culture negative, would 
potentially improve control and eradication. Thus, parallel testing may be strategically 
applied to maximise the detection of M. bovis-infected buffaloes in a disease control setting 
(Bernitz et al., 2018b). 
 
In addition to the Sp and suggested Se of the QFT IGRA and IPRA in parallel, this test 
combination has a cost advantage associated with handling the animals. To perform the 
SCITT on buffaloes (and other wildlife species), animals need to be immobilised twice and 
are often held captive for the three days between immobilizations. For the QFT assays, 
animals need only be immobilised on a single occasion and blood can be collected directly 
into the test tubes. After incubation, tubes are centrifuged and the plasma is separated by a gel 
plug which allows for immediate testing of plasma or storage prior to shipping to a diagnostic 
laboratory. The QFT system also has the advantage of ease-of-use under field conditions 
compared to the Bovigam® IGRA, which requires trained laboratory technicians to perform 
antigen stimulations and plasma harvesting. Costs and effort are also reduced by measuring 
two biomarkers from the same plasma sample and, since there is no in vivo sensitization with 
these tests, they can be repeated without a waiting period, as is required for the SCITT. 
 
A limitation of this study is that only 51 M. bovis culture-confirmed buffaloes were included 
in our analyses and therefore, true differences in assay performance may not have been 
detected due to the small sample size. No spectrum bias was introduced into this study due to 
the fact that: i) M. bovis-unexposed buffaloes were sourced from more than five 





tested from two geographically isolated M. bovis-endemic reserves, and post mortem 
examinations of these buffaloes revealed a broad spectrum of bTB disease in these 
populations. Notably, the data from this study should be strategically applied to similar M. 
bovis-endemic populations. Finally, the diagnostic sensitivities of the assays could not be 
estimated due to the selection bias introduced by only using culture-positive buffaloes 
selected based on prior test results. Thus, only the differences between the proportion of 
animals identified by each test and parallel interpretations of selected tests were calculated. 
Future studies should evaluate the performance of tests to detect M. bovis infection in 
buffaloes in randomly selected, unbiased sample populations. 
 
In conclusion, the parallel measurement of IFN-γ and IP-10 in the QFT system maximised 
detection of M. bovis-infected African buffaloes. This blood-based assay may be a preferred 
method to increase detection of infected animals while maintaining test Sp and simplifying 
bTB test procedures. 
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The chemokine interferon gamma-inducible protein-10 (IP-10) is a sensitive biomarker of 
Mycobacterium bovis (M. bovis) infection in African buffaloes (Syncerus caffer). However, 
elevated levels of IP-10 in QuantiFERON®-TB Gold (QFT) unstimulated whole blood 
compromises the utility of this biomarker. In this study, IP-10 and interferon gamma (IFN-γ) 
concentrations in whole blood samples from M. bovis culture-confirmed buffaloes with 
varying degrees of pathological changes (n = 72) and uninfected controls (n = 70) were 
measured in IP-10 release assay (IPRA) and QFT IFN-γ release assay (IGRA), respectively. 
Findings suggest that concentrations of both IP-10 and IFN-γ in QFT Nil tubes were higher in 
infected buffaloes with macroscopic pathological changes consistent with bovine tuberculosis 
compared to uninfected controls, and IGRA values increased with more severe pathological 
changes in infected buffaloes (p < 0.05). Finally, in culture-confirmed buffaloes with IPRA-
negative and IGRA-positive test results, most animals were also those with the most 
advanced pathology. We conclude that IP-10 and IFN-γ concentrations measured in QFT Nil 
tubes may provide insight into the presence of M. bovis pathology in infected buffaloes. 
Furthermore, this study highlights the value in evaluating cytokine production in both 






1. Introduction  
Bovine tuberculosis (bTB) is a chronic inflammatory disease caused by the pathogen 
Mycobacterium bovis (M. bovis). Mycobacterium bovis has a wide mammalian host range 
including domestic animals, wildlife, livestock and humans (Hlokwe et al., 2014; Dippenaar 
et al., 2017). The disease is characterised by granulomas, formed when host immune cells 
infiltrate the tissue at the site of infection. Aggregates of infected macrophages fuse to form 
multinucleated giant cells followed by localised fibrosis and encapsulation (Palmer et al., 
2007). These lesions are initially microscopic but with chronic inflammation, they increase in 
size. Granulomas mature and multi-focal lesions may coalesce and become diffuse in the 
infected tissue, with caseous necrotic centers. Advanced bTB may result in morbidity and 
mortality (Domingo et al., 2014). 
 
In South Africa (SA), African buffaloes (Syncerus caffer) are wildlife reservoirs of M. bovis 
and thus efforts to control bTB disease in buffaloes are aimed at reducing infection in this 
species and spread to others. Since bTB is a chronic disease, buffaloes may present with 
clinical signs only after months or years of infection. Subsequently, strategies to identify M. 
bovis-infected buffaloes utilise measurement of early antigen-specific cell-mediated immune 
responses against M. bovis antigens, rather than clinical disease. The early detection of 
infected buffaloes may enable management strategies to be implemented soon enough to limit 
the transmission of M. bovis. 
 
In order to do this, in vitro cytokine release assays have been developed to quantify the 
production of cytokine biomarkers in plasma in response to antigen-specific whole blood 
stimulation. The QuantiFERON®-TB Gold (QFT) system is an easy-to-use stimulation 





tube containing early secretory antigen target 6kD (ESAT-6), culture filtrate protein 10kD 
(CFP-10) and TB 7.7(p4) (stimulated) and iii) mitogen tube containing phytohemagglutinin 
(positive control). The interferon gamma-inducible protein-10 (IP-10) release assay (IPRA) 
and the interferon gamma (IFN-γ) release assay (IGRA) measure the cytokines IP-10 and 
IFN-γ in plasma, respectively, following QFT whole blood stimulation (Bernitz et al., 2019). 
The QFT IPRA and IGRA results are calculated as the plasma concentration of the cytokine 
in the QFT Nil tube subtracted from the plasma concentration of the cytokine in the QFT TB 
antigen tube. The QFT IPRA is highly sensitive and specific for detecting M. bovis-infection 
in buffaloes (Bernitz et al., 2019), however, the utility of the assay may be compromised by 
high concentrations of IP-10 in the QFT Nil tube ([IP-10Nil]). This may cause false-negative 
test results in truly infected buffaloes and hinder the diagnostic performance of the QFT 
IPRA. 
 
The phenomenon of elevated [IP-10Nil] has been observed in humans and cattle and although 
not understood in the latter, has been associated with extent of disease in humans (Chen et al., 
2011; Parsons et al., 2016). Therefore, the aim of this study was to evaluate the QFT IGRA 
and IPRA in terms of the spectrum of bTB pathology. The [IP-10Nil] and the concentration of 
IFN-γ in the QFT Nil tube ([IFN-γNil]) within groups of M. bovis culture-confirmed buffaloes 
with variable lesions were compared to uninfected controls. Furthermore, the magnitude of 
QFT IPRA and IGRA values and discordant QFT assay results between groups of culture-









2. Materials and methods 
2.1. Animals 
A total of 786 buffaloes were tested using the QFT IPRA and IGRA during bTB test-and-cull 
programmes in Hluhluwe iMfolozi Park, South Africa during 2016, 2017 and 2018. All test 
positive animals were culled and underwent post mortem examination as described below (n 
= 145), of which all animals confirmed positive on mycobacterial culture were used in this 
study (n = 72). During the same period, buffaloes from eight farms in SA with no known 
history of bTB were opportunistically tested with the QFT IPRA and IGRA when 
immobilised for reasons unrelated to this study. These buffaloes were used as uninfected 
controls (n = 70). 
 
2.2. QFT IPRA and IGRA 
Both cytokine release assays were performed on all buffaloes as previously described 
(Bernitz et al., 2019). Briefly, within eight hours of blood collection, 1 ml aliquots of 
heparinised whole blood were aseptically transferred to tubes of the QFT system (Qiagen, 
Venlo, Limburg, Netherlands); i) Nil; ii) TB antigen, and iii) mitogen (respectively). Samples 
were inverted ten times and incubated for 20 h at 37 °C. Plasma was harvested following 
centrifugation. The cytokine IP-10 was measured using an in-house bovine-specific IP-10 
enzyme-linked immunosorbent assay (ELISA) (Kingfisher Biotech Inc., St Paul, MN, USA) 
and IFN-γ was measured using the commercially available cattletype® IFN-gamma ELISA 
(Qiagen, Venlo, Limburg, Netherlands). The IPRA results were calculated as the [IP-10Nil] 
subtracted from the concentration of IP-10 in the QFT TB antigen tube ([IP-10TB]). An IPRA-
positive result was defined as a differential concentration of IP-10 ≥ 1486 pg/ml (Goosen et 
al., 2015). In contrast, the IGRA results were calculated as sample to positive control (S/P) 





cattletype® IFN-gamma ELISA positive control – OD cattletype® IFN-gamma ELISA 
negative control) x 100. A positive IGRA result was defined as S/P ≥ 35%. All M. bovis-
uninfected control buffaloes were test-negative on both the QFT IPRA and IGRA (data not 
shown). 
 
2.3. Post mortem examinations and mycobacterial culture 
Buffaloes that tested positive on one or both QFT assays were euthanased by gunshot and 
examined for gross bTB lesions during post mortem examination. Lymph nodes of the head 
and thoracic cavity, and lungs were carefully dissected. Macroscopic pathological changes 
consistent with bTB were scored as follows: L1, one small focal lesion (diameter < 10 mm); 
L2, several small foci or a single lesion (diameter ≥ 10 mm and < 30 mm); and L3, a single 
lesion (diameter ≥ 30 mm) or multifocal/confluent lesions (Palmer et al., 2007). In addition to 
the lesion score, a subjective description was recorded. To limit variation in lesion scoring, a 
single experienced veterinarian scored the lesions from all buffaloes. The lesion scores were 
used as a measure of pathological changes due to M. bovis infection. If an animal had no 
visible lesions (NVL), this was recorded, and pooled tissue samples of head (parotid, 
retropharyngeal, submandibular, and tonsils) and thoracic (mediastinal and tracheobronchial) 
lymph nodes were collected. Mycobacterial culture and genetic speciation were performed on 
all lesions and pooled tissue samples to confirm M. bovis infection as previously described 
(Goosen et al., 2014).  
 
2.4. Data analyses 
A Kruskal-Wallis one-way ANOVA with a Dunn’s post-test was used to compare i) [IP-
10Nil] and [IFN-γNil] in M. bovis-unexposed buffaloes and groups of culture-confirmed 





culture-confirmed buffaloes with different lesion scores [GraphPad Prism version 5 software 
(GraphPad Software Inc., San Diego, CA, USA)]. Differences were considered statistically 
significant if p < 0.05. A Cochran’s Q test with Bonferroni correction for multiple 
comparisons was used to compare the proportions of culture-confirmed buffaloes with 
concordant and discordant QFT assay results in each of the lesion score groups (MedCalc 
Free Trial Version 19.03 https://www.medcalc.org/download.php). Differences were 




Table 6.1 Concordant and discordant QFT assay results in M. bovis culture-confirmed (n = 
72) buffaloes with no visible lesions (NVL) and lesion scores of 1 to 3 (L1-3): L1, one small 
focal lesion (diameter < 10 mm); L2, several small foci or a single lesion (diameter ≥ 10 mm 
and < 30 mm); and L3, a single lesion (diameter ≥ 30 mm) or multifocal/confluent lesions. 
Superscript numbers denote differences that are statistically significant (p = 0.002). 
Lesion score IPRAa+b IGRAc+ IPRA-d IGRA+ IPRA+ IGRA- 
NVL 6 01 6 
L1 4 4 11 
L2 13 02 8 
L3 8 81,2 4 
Total 31 12 29 
a interferon gamma-inducible protein-10 release assay  
b test positive 
c interferon gamma release assay 



























Figure 6.1 The magnitude of IP-10 concentrations in unstimulated whole blood samples 
(QFT Nil tubes) from uninfected controls (n = 70) and M. bovis culture-confirmed buffaloes 
(n = 72) with no visible lesions (NVL) and lesion scores 1-3 (L1-3). Horizontal bars 
represent median and interquartile ranges. P-values were calculated, and differences were 
considered statistically significant if p < 0.05 (** p < 0.001). 
 
Median [IP-10Nil] were significantly higher in M. bovis culture-confirmed buffaloes with 
lesion scores of L1, L2 and L3 compared to uninfected controls (p < 0.001; Figure 6.1). 
Similarly, median [IFN-γNil] were significantly higher in animals with lesions (L2, L3) than 
uninfected controls (p < 0.001). Moreover, culture-confirmed buffaloes with the highest 
lesion score (L3) had median [IFN-γ
Nil] that were significantly higher than those with NVL (p 




























Figure 6.2 The magnitude of IFN-γ concentrations in unstimulated whole blood samples 
(QFT Nil tubes) from uninfected controls (n = 70) and M. bovis culture-confirmed buffaloes 
(n = 72) with no visible lesions (NVL) and lesion scores 1-3 (L1-3). Horizontal bars represent 
median and interquartile ranges. P-values were calculated, and differences were considered 
statistically significant if p < 0.05 (* p < 0.05 and ** p < 0.001). 
 
There were no statistical differences in IPRA values between culture-confirmed buffaloes 
with different lesion scores (Figure 6.3). However, median IGRA values for buffaloes with 
higher lesion scores (L2 and L3) were significantly higher than median values for buffaloes 





























Figure 6.3 The magnitude of QFT IPRA values in M. bovis-culture confirmed buffaloes with 
no visible lesions (NVL) and lesion scores 1-3 (L1-3) (n = 72). The cutoff value for the assay 
is indicated by the dotted line (1486 pg/ml). Horizontal bars represent median and 
interquartile ranges. No statistical differences were observed between lesion score groups. 
 
The proportion of IPRA-positive IGRA-positive buffaloes in different lesion score groups 
were not significantly different. In contrast, the greatest proportion of IPRA-negative IGRA-
positive buffaloes had the highest lesion score (L3) and this was a significantly greater than 
the proportion of animals with NVL or L2 (p = 0.002). Furthermore, the greatest proportion 
of IPRA-positive IGRA-negative buffaloes had the lowest lesion score (L1), although this 
was not significantly different from the proportions of buffaloes with other lesion scores 




































Figure 6.4 The magnitude of QFT IGRA values in M. bovis culture-confirmed buffaloes with 
no visible lesions (NVL) and lesion scores 1-3 (L1-3) (n = 72). The cutoff value for the assay 
is indicated by the dotted line (S/P = 35%). Horizontal bars represent median and 
interquartile ranges. P-values were calculated, and differences were considered statistically 
significant if p < 0.05 (* p < 0.05 and ** p < 0.001). 
 
4. Discussion 
In this study, pathological changes were assessed by the presence and size of macroscopic 
bTB lesions in the lymph nodes and lungs of M. bovis culture-confirmed buffaloes. We 
evaluated antigen-stimulated and unstimulated cytokine production to interpret the QFT 
IPRA and IGRA results in the context of bTB pathology in buffaloes. 
 
Both the [IP-10Nil] and [IFN-γNil] were higher in buffaloes with culture-confirmed lesions 





lesion scores. This is consistent with studies showing the production of IP-10 and IFN-γ in 
unstimulated samples from human patients with active tuberculosis is higher than in 
uninfected controls, and unstimulated IFN-γ concentrations increase during the progression 
of active tuberculosis (Hasan et al., 2009). Additionally, both cytokines are included in an ex 
vivo biomarker signature for the diagnosis of active tuberculosis in humans (Hussain et al., 
2010; Chen et al., 2011; Chegou et al., 2016). Therefore, the [IP-10Nil] and [IFN-γNil] should 
be interpreted along with antigen-stimulated results, when analysing QFT cytokine release 
assay results to improve the detection of bTB in buffaloes. 
 
 
In culture-confirmed buffaloes, QFT IGRA values increased as pathological changes 
increased. The cytokine IFN-γ is the archetypal measure of the Th1 immune pathway 
activated in response to Mycobacterium tuberculosis (Mtb) or M. bovis infection. These 
findings are consistent with studies in cattle, humans and European badgers (Meles meles) 
that have demonstrated a correlation between antigen-stimulated IFN-γ concentrations and 
disease severity (Vordermeier et al., 2002; Sahiratmadja et al., 2007; Tomlinson et al., 2015). 
Therefore, antigen-stimulated IFN-γ may not only be a biomarker of M. bovis infection but 
may provide information regarding the presence of bTB pathology in buffaloes.  
 
In contrast to the QFT IGRA, IPRA values did not differ among groups of culture-confirmed 
buffaloes with different lesion scores. We propose that high levels of antigen-stimulated IP-
10 are produced in animals recently infected with M. bovis and so there is no marked 
difference between concentrations measured in culture-confirmed buffaloes with and without 
pathological changes. Supporting this, a study reported no significant differences between 
antigen-stimulated IP-10 in children with latent Mtb-infection and those with active disease 





In M. bovis culture-confirmed IPRA-positive IGRA-negative buffaloes, a greater proportion 
of animals presented with early signs of disease (L1) compared to those with higher lesion 
scores. As discussed above, the cytokine IP-10 is a highly sensitive biomarker of infection 
and is suggested to detect buffaloes recently infected with M. bovis. The cytokine IP-10 is 
produced more than 2000-fold compared to IFN-γ (McInnis et al., 2005) and can therefore be 
measured at an earlier stage of infection when IFN-γ may not yet be detectable (Ruhwald et 
al., 2007). Therefore, we propose that IPRA-positive IGRA-negative buffaloes are animals 
that have recently been infected and this is supported by the findings of early lesions in these 
animals (Table 6.2). While IP-10 may not specifically be associated with development of 
pathological changes, this study confirms the use of IP-10 as a valuable biomarker of M. 
bovis infection in buffaloes.  
 
Table 6.2 Interpretation of QFT assay result permutations to detect infection and 
macroscopic pathology in buffaloes from a Mycobacterium bovis-endemic population. 
IPRAa IGRAb Infection status  Further interpretation  
Negative Negative Uninfected No macroscopic pathology 
Positive Negative* Early-infection No or early macroscopic pathology  
Positive Positive Infected Early macroscopic pathology  
Negative** Positive Chronically infected Advanced macroscopic pathology 
a interferon gamma-inducible protein-10 release assay  
b interferon gamma release assay 
* IFN-γ may not yet be at detectable levels 






In culture-confirmed IPRA-negative IGRA-positive buffaloes, a significantly greater 
proportion of animals had evidence of pathology compared to those with NVL. We propose 
that buffaloes with bTB lesions produce higher [IP-10Nil] decreasing the IP-10 differential 
value between antigen-stimulated and unstimulated samples, resulting in an IPRA-negative 
result. This is supported by the observation that 5 of the 12 IPRA-negative IGRA-positive 
buffaloes in this study with bTB pathology, had higher [IP-10Nil] compared to [IP-10TB]. 
Thus, IPRA results with high [IP-10Nil] should be regarded as inconclusive and not test-
negative, whereas a buffalo that is IPRA-negative IGRA-positive should be suspected of 
having bTB pathology, if the [IP-10Nil] is elevated (Table 6.2). An IPRA-negative (due to 
elevated [IP-10Nil]) IGRA-positive result may have practical diagnostic relevance as a risk-
based approach to culling the most infectious animals first, as bTB diseased animals are more 
likely to shed bacteria thereby transmitting infection. 
 
A limitation of this study includes the low sample numbers that may mask statistically 
significant differences. Moreover, in this study, lesion scores were used as a measure of 
pathological changes due to M. bovis infection. However, to investigate the extent of disease, 
additional criteria including body condition, dissemination of bTB to other organs and 
histopathology would need to be examined. Future studies should be performed in larger 
buffalo cohorts to determine cutoff values for the [IP-10Nil] and [IFN-γNil] that may indicate 
M. bovis infection versus disease. 
 
In conclusion, this study demonstrates that the magnitude of IP-10 and IFN-γ concentrations 
in QFT-processed whole blood can be used as an indicator of bTB pathology in buffaloes. 





positive QFT IGRA result, may be suggestive of the presence of disease due to M. bovis 
infection in buffaloes. 
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A herd of buffaloes was tested for Mycobacterium bovis infection using three cytokine 
release assays. All animals were subsequently euthanased and mycobacterial culture was used 
to determine the infection prevalence (52%) and diagnostic performances. Sensitivities were 







The Bovigam® interferon-gamma (IFN-γ) release assay (IGRA), QuantiFERON®-TB Gold 
(QFT) IGRA and QFT IFN-γ-inducible protein-10 (IP-10) release assay (IPRA) have been 
used to detect Mycobacterium bovis (M. bovis) infection in African buffaloes (Syncerus 
caffer) (Goosen et al., 2015; Bernitz et al., 2018). The sensitivity (Se) and specificity (Sp) of 
these assays have previously been calculated to evaluate their diagnostic performances 
(Michel et al., 2011; Bernitz et al., 2019). Sensitivity was calculated as the proportion of test-
positive culture-confirmed buffaloes (i.e., animals selected based on a positive M. bovis test 
result which had confirmed infection based on culture) correctly diagnosed. Specificity was 
calculated as the proportion of test-negative buffaloes correctly diagnosed in M. bovis-
unexposed controls. 
 
Sensitivity and Sp describe the performance of an assay at a given cutoff, and are 
independent of the population’s infection prevalence. From a clinical perspective, the 
predictive values of a test are more relevant, i.e. the probability of an individual with a 
positive or negative test outcome being truly infected or uninfected, respectively (Trevethan 
et al., 2017). Positive and negative predictive values (PPV and NPV) are dependent on both 
the technical characteristics of the test (Se and Sp) as well as the infection prevalence 
(Grunau and Linn 2018). Therefore, in order to evaluate the diagnostic performance of an 
assay in a clinical context, gold standard criteria need to be applied to an unbiased sample, 
independent of prior selection. In the case of M. bovis infection, mycobacterial culture is the 
gold standard, and therefore, an entire herd would need to be euthanased to determine the 







2. Materials and methods 
During 2018 in Hluhluwe iMfolozi Park (HiP), South Africa (SA), a herd of 50 buffaloes was 
captured, immobilised and whole blood collected as described by Parsons et al. (2011). 
 
The Bovigam® IGRA (Prionics AG, Schlieren-Zurich, Switzerland) was performed as 
previously described (Bernitz et al., 2018). The QFT IGRA (Qiagen, Venlo, Limburg, 
Netherlands) and QFT IPRA were performed as described by Bernitz et al. (2019) with the 
exception that the QFT Plus system was used for whole blood stimulation. The QFT-Plus 
system has two antigen tubes, namely i) TB1 which contains the same ESAT-6 and CFP-10 
antigen peptides as the original QFT system, but not TB7.7(p4), and ii) TB2 which contains 
the same peptides as TB1 plus additional peptides for human application (Theel et al., 2018). 
No differences were observed when either antigen tubes (TB1 or TB2) were used to interpret 
the assays and on instruction from the manufacturer, TB2 was used to calculate assay results.  
 
All animals were euthanased due to a suspected high infection prevalence based on test 
results (> 50% of buffaloes were test-positive on one or more assay). Buffaloes underwent 
necropsy as previously described in detail (Bernitz et al. 2019b) and mycobacterial culture, 
using the BACTEC™ MGIT™ 960 Mycobacterial Detection System (Becton Dickinson, 
Franklin Lakes, NJ, USA).  
 
The infection prevalence, Se, Sp and predictive values for each assay and parallel 
interpretation of the QFT IGRA and QFT IPRA assays (QFTparallel), a QFTparallel-positive 
result defined as one or both assays being test-positive (Bernitz et al., 2019a), were calculated 






3. Results and discussion 
The infection prevalence of the herd was 52%, based on culture. The Se of assays determined 
in this study (Table 7.1) were lower than those previously calculated. Studies have reported 
Se of 80% for QFT IGRA (Bernitz et al., 2019), 80-100% for Bovigam® IGRA (Michel et al., 
2011; Bernitz et al., 2018) and 100% for both the QFT IPRA and QFTparallel (Bernitz et al., 
2019). However, only test-positive culture-confirmed buffaloes were used in these studies 
and therefore, truly infected test-negative buffaloes would not have been included, resulting 
in an overestimation of Se. Results of this study suggest biased sampling (when the reference 
test is interpreted with knowledge of the test result) may lead to overestimations of Se, and 
lower detection rates of truly infected animals when applied in control programmes. 
 
The assay Sp calculated in this study (Table 7.1) were also lower than those previously 
reported based on M. bovis-unexposed controls, which were 95% for Bovigam® IGRA and 
100% for individual QFT assays and QFTparallel (Michel et al., 2011; Bernitz et al., 2019). 
Although it is common practise to use endemic controls to calculate the Sp of assays in 
human studies, it was expected that use of culture-negative endemic controls in this study 
would result in an underestimation of Sp due to the suboptimal performance of culture as a 
gold standard (de la Rua-Domenech et al., 2006). Future studies should use M. bovis-






Table 7.1 Test performances [sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV)] with 95% 
confidence intervals of in vitro cytokine release assays in detecting Mycobacterium bovis infection in African buffaloes (Syncerus caffer), based 
on mycobacterial culture results in a herd with an infection prevalence of 52% (n = 50). 
Test/s 
Culture-positive (n = 26) Culture-negative (n = 24) 
Se (95% CI) NPV (95% CI) Sp (95% CI) PPV (95% CI) 
True positive False negative False positive True negative 
Bovigam® IGRA a 19 7 2 22 73 (52-88) 76 (62-86) 92 (73-99) 90 (71-97) 
QFT IGRA b 10 16 1 23 38 (20-59) 59 (51-66) 96 (79-100) 91 (58-99) 
QFT IPRA c 18 8 8 16 69 (48-86) 67 (51-79) 67 (45-84) 69 (55-81) 
QFTparallel d 21 5 9 15 81 (61-93) 75 (56-87) 63 (41-81) 70 (57-80) 
aBovigam® interferon gamma release assay  
bQuantiFERON®-TB Gold Plus interferon gamma release assay 
cQuantiFERON®-TB Gold Plus interferon gamma-inducible protein-10 release assay 
dparallel interpretation of the QuantiFERON®-TB Gold Plus IGRA and IPRA
Stellenbosch University https://scholar.sun.ac.za
 
The assay NPVs were 59-76% and the PPVs 69-91% (Table 7.1) in this high prevalence herd. 
These metrics have not been previously reported for these assays. Assays with high NPVs 
would be useful for herds in eradication schemes to increase confidence in a negative test 
result, as leaving a test-negative infected animal may maintain infection (Clegg et al., 2019). 
Similarly, assays with high PPVs would be useful in testing valuable infected or previously 
uninfected herds, where confidence in a positive test result is required, as a false-positive 
result may result in the unnecessary euthanasia of a healthy animal or a farm being placed 
under quarantine. 
 
A limitation of this study is that culture is an imperfect gold standard, especially during early 
infection, and the QFT IPRA has high Se in buffaloes with early infection (Bernitz et al., 
under review). Thus, the infection status of some IPRA-positive buffaloes may be 
misinterpreted as negative (Bernitz et al., 2019). Furthermore, the small sample size limited 
statistical analyses and interpretation of data in this study. Despite this, the predictive values 
calculated provide estimated levels of confidence in test results in high prevalence herds.  
In this pilot study, a whole buffalo herd tested using three cytokine release assays was 
euthanased, enabling the infection prevalence of the herd and the test performances of the 
assays to be calculated using an unbiased sample. Our results suggest assay Se have 
previously been overestimated, while the assay Sp were underestimated in this study. Future 
studies using larger unbiased sample populations are required so that statistical analyses can 
be performed to compare test performances and avoid any selection bias that may prejudice 
test results. The consequence of this study is that eradication of M. bovis infection in South 
Africa may be prolonged by the diagnostic performances of established assays that are lower 
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Chapter 8 : Flow cytometric analysis of interferon gamma-inducible 









The QuantiFERON® TB Gold (QFT) interferon gamma-inducible protein-10 (IP-10) release 
assay (IPRA) is a sensitive and specific assay to detect Mycobacterium bovis (M. bovis) 
infection in African buffaloes (Syncerus caffer). However, elevated levels of IP-10 in 
unstimulated QFT whole blood of some buffaloes may compromise the utility of this IPRA. 
In buffaloes and cattle, the cellular source of IP-10 in peripheral blood is unknown and the 
aim of the present study was to develop a multiplex flow cytometry protocol to determine the 
major phenotypes of immune cells that produce IP-10 in cattle peripheral blood. Leukocytes 
from unstimulated and mitogen-stimulated whole blood samples of ten cattle were labelled 
with a panel of bovine cross-reactive antibodies in order to detect IP-10 production in 
selected cell phenotypes. An IP-10 signal was detected in all cell subsets and no differences 
were observed between unstimulated and mitogen-stimulated samples. As a result, the IP-10 
antibody signal was not specific for the cytokine and therefore, further optimisation of the 






Strategies to identify Mycobacterium bovis (M. bovis) infection in buffaloes rely on 
measurements of early cell-mediated immune responses towards mycobacterial antigens 
(Goosen et al., 2014). In vitro cytokine release assays quantify the production of cytokine 
biomarkers in plasma in response to M. bovis antigen-specific whole blood stimulation. The 
interferon gamma-inducible protein-10 (IP-10) release assay (IPRA) measures the cytokine 
IP-10 in QuantiFERON® TB-Gold (QFT) stimulated whole blood to detect M. bovis infection 
in buffaloes (Bernitz et al., 2019). The QFT system is an easy-to-use stimulation platform 
comprised of i) Nil tube containing saline (unstimulated control), ii) TB antigen tube 
containing specific mycobacterial peptides (stimulated) and iii) mitogen tube containing 
phytohemagglutinin (positive control).  
 
The cytokine IP-10 is a sensitive biomarker of M. bovis infection in buffaloes (Goosen et al., 
2015), however the utility of the biomarker in the QFT IPRA is compromised by high 
concentrations of IP-10 in the QFT Nil tube. This may cause false-negative test results in 
truly infected buffaloes and hinders the diagnostic performance of the QFT IPRA. Elevated 
levels of IP-10 in the QFT Nil tube have also been reported in cattle, but this phenomenon is 
not understood in this species (Parsons et al., 2016). In humans, studies have suggested that 
elevated levels of IP-10 in unstimulated whole blood samples may be due to active 
tuberculosis (Chen et al., 2011). In buffaloes, a study is underway to determine if this is also 
true for buffaloes and bovine tuberculosis (Bernitz et al., under review). In order to 
understand the mechanisms behind IP-10 production in unstimulated buffalo whole blood, the 
cellular source of IP-10 needs to be identified. In humans, IP-10 has numerous cellular 





lymphocytes (Cassatella et al., 1997; Gasperini et al., 1999; Antonelli et al., 2014; Hoff et al., 
2015), while in cattle and buffaloes, the cellular source of IP-10 is unknown.  
 
Collecting blood samples from buffaloes is logistically challenging and for this reason, this 
study was performed in cattle with the intention of using the optimised methods and results to 
investigate IP-10 production in buffaloes. This study aimed to identify the cellular sources of 
IP-10 in cattle peripheral blood using flow cytometric analysis by identifying the phenotypes 
of leukocytes that are able to produce IP-10 under stimulation conditions.  
 
1. Materials and methods 
1.1. Sample collection and blood processing 
On day one, 6 ml of blood was collected into heparinised tubes from the tail vein of ten 
Holstein cattle at the Stellenbosch University’s Welgevallen Experimental Farm, South 
Africa. All animals were in the milking line-up and therefore considered healthy. Within four 
hours, blood from each cow was processed in 5 ml tubes under two conditions, i.e., i) 
stimulated, for which a 2 ml aliquot of blood was incubated with 25 µl pokeweed mitogen 
(PWM), 5 µg/ml final concentration (Sigma-Aldrich, St. Louis, Missouri, USA), and ii) 
unstimulated, for which a 2 ml aliquot of blood was incubated with phosphate buffered 
saline. The samples were thoroughly mixed and incubated at 37 °C for 6 h after which 10 µl 
brefeldin-A, 10 µg/ml final concentration (Sigma-Aldrich) was added to all samples. The 
samples were once more thoroughly mixed and incubated for a further 18 h. 
 
1.2. Titrations 
Titrations were performed prior to the final experiment to determine the optimal 





the concentration of antibody recommended by the manufacturer. A dilution series was 
prepared including a dilution to achieve this recommended antibody concentration, as well as 
half this dilution (double the recommended concentration) and double this dilution four times 
(four concentrations lower than the recommended concentration). For the titrations, 200 µl 
aliquots of whole blood in 96-well plates were centrifuged and the supernatant removed. The 
cells were thereafter stained in a total volume of 20 µl. The staining index, the ratio of the 
separation between the positive and negative populations divided by two times the standard 
deviation of the negative population, was used to determine each optimal antibody 
concentration (Appendix 8.1).  
 
1.3. Surface marker staining  
Following 24 h incubation, 200 µl aliquots of stimulated and unstimulated whole blood was 
added to wells of a 96-well plate and centrifuged at 400 x g for 5 min. The supernatant was 
removed and a master mix (MM) of surface marker antibodies and a viability cell marker at 
optimised concentrations, in BD Perm/Wash™ buffer (BD Biosciences, San Jose, CA, USA), 
diluted in water and freshly prepared, was added to the cell pellet (Table 8.1). Plates were 
incubated in the dark for 1 h at room temperature (RT).  
 
1.4. Red cell lysis of whole blood 
Incubated whole blood samples were centrifuged and the supernatant was removed. BD 
FACS™ lysing solution 10X concentrate (BD Biosciences), diluted in water, was added to 
the cell pellet and red cell lysis was performed in the dark for 15 min at RT. Samples were 







1.5. Intracellular maker staining  
Cells were incubated in BD Perm/Wash™ buffer in the dark for 15 min at RT. Samples were 
centrifuged and washed twice in BD Perm/Wash™ buffer. Cells were resuspended in a MM 
of the biotinylated anti-IP-10 and anti-CD3 (Alexa Flour® 700) antibody, at optimised 
concentrations (Table 8.1), and incubated in the dark for 40 min at RT. After incubation, cells 
were washed twice in BD Perm/Wash™ buffer and then stained with PE-Cy™7-conjugated 
streptavidin at an optimised concentration (Table 8.1). Cells were washed twice and 
resuspended in BD Perm/Wash™ buffer. All samples were processed and stained on the 
same day. The BD LSR II flow cytometer (BD Biosciences) was used for cell acquisition (≥ 
10 000 events). The cytometer was calibrated per the manufacturer’s instructions and 
compensation settings were adjusted using BD™ CompBeads (BD Biosciences).  
 
1.6. Data analyses and gating strategies  
Data were analysed using FlowJo Version 10 software (Tree Star, Ashland, OR, USA). 
Initially, a gating strategy was applied in order to obtain data that included a stable flow 
stream and excluded cell doublets, debris and non-viable cells: i) time versus side scatter area 
(SSC-A) was used to ensure an even flow of acquired cells; ii) forward scatter area (FSC-A) 
versus FSC height (FSC-H) was used to identify and include singlets and exclude doublets; 
iii) FSC-A versus SSC-A was used to exclude cell debris based on size and granularity of 
cells; and iv) a viability stain was used to include viable cells and exclude non-viable cells 
(Table 8.2, Figure 8.1A-D). A diagonal belt of signal believed to be autofluorescence and 





Table 8.1 Reagents optimised to identify subsets of leukocytes that produce IP-10 in cattle whole blood. 





CD3 CD3-12 AF700 human, bovine Bio-Rad MCA1477A700 neat 1:4 
CD4 CC8 AF647 bovine Bio-Rad MCA1653A647 neat-1:10 1:20 
CD21 LT21 PE-Cy5® human, bovine Abcam ab201303 1:5 1:12.5 
CD335 AKS1 PE bovine Bio-Rad MCA2365PE Neat 1:5 
CD16 KD1 FITC human, bovine Bio-Rad  MCA5665F neat-1:10 1:8 
CD14 M5E2 APC/Cy7 human, bovine BioLegend 301819 none given 1:80 
biotinylated IP-10  pAb none bovine Kingfisher PBB0393B-050 none given 1:10 000 
streptavidin N/A PE-Cy™7 N/A BD Biosciences 557598 none given 1:6400 






The proportion of each cell subset that produced IP-10 was calculated as the proportion of 
CD3+/CD4+, CD3+/CD4-, CD3+/CD335+, CD3-/CD335+, CD3-/CD21+, CD3-/CD14+ and 
CD3-/CD16+ cells displaying an IP-10+ signal (Figure 8.1F-I). A one-way ANOVA was used 
to compare median IP-10 signals in unstimulated and stimulated samples using GraphPad 
Prism version 5 software (GraphPad Software Inc., San Diego, CA, USA). Differences were 
considered statistically significant if p < 0.05. 
 
2. Results and discussion  
2.1. Phenotyping 
Scatter plots of Alexa Flour® 700 (CD3) versus SSC-A identified two distinct populations: 
CD3+ cells and CD3- cells. The mean percentages of the CD3+ and CD3- cells were 36.9% (± 
16.2%) and 59.8% (± 16.13%) of all leukocytes, respectively (Figure 8.1E, Table 8.3).  
 
All CD3+ cells were gated on to analyse CD4 (Figure 8.1F) and CD335 expression (Figure 
8.1G). Three distinct populations were identified, namely CD3+/CD4+ cells designated as 
CD4 T lymphocytes, CD3+/CD4- cells designated as CD8 T lymphocytes, and CD3+/CD335+ 
cells designated as Natural Killer (NK) T (NK-T) lymphocytes (Kim et al., 2016). The mean 
percentages of CD3+/CD4+ and CD3+/CD4- cells were 12.5% (± 7.7%) and 24.2% (± 8.5%) 
of all leukocytes, respectively (Table 8.3). This finding is in agreement with studies reporting 
peripheral blood from cattle is comprised of more CD8+ cells than CD4+ cells (Soltys and 
Quinn, 1999; Guzman et al., 2014). The stage of lactation has shown to affect the frequencies 
of leukocytes in peripheral blood of healthy cattle, however it appears that CD8 remains the 







Table 8.2 The percentage of cells selected by specific gating strategies as a percentage of 
parent population from 10 ex vivo cattle whole blood samples after red blood cell lysis. 
Cow ID Time (%) Single cells (%) Size and granularity (%) Viable cells (%) 
1 93.2 88.3 92.2 78.6 
2 93.3 82.8 79.5 74.4 
3 96.3 86.0 84.5 70.6 
4 86.7 77.8 69.1 69.5 
5 91.3 75.1 65.0 87.4 
6 88.5 71.9 61.2 69.9 
7 79.4 76.8 69.6 79.4 
8 93.7 86.9 88.7 87.7 
9 98.4 82.1 82.5 78.4 
10 93.3 74.0 64.8 76.3 
Mean 91.4 80.2 75.7 77.2 
SD 5.4 5.8 11.1 6.6 
 
The small proportion of CD3+/CD335+ cells (1.1 ± 0.9% of total leukocytes) identified in this 
study (Table 8.3) is comparable to the 0.1-1.7% of NK-T cells previously reported for cattle 
in isolated peripheral blood mononuclear cells (Connelley et al., 2014). This non-
conventional T lymphocyte subset that shares functional properties with both conventional 
NK and T-cells, was only identified in cattle in 2014 (Connelley et al., 2014). Limited 
literature on the frequencies of NK-T cells in whole blood is available with which to directly 






All CD3- cells were gated on to analyse CD335 (Figure 8.1H), CD21 (Figure 8.1I), CD14 and 
CD16 expression (Figure 8.1J). Four distinct populations were identified, namely CD3-
/CD335+ cells designated as NK cells (Hussen et al., 2013), CD3-/CD21+ cells designated as 
B lymphocytes (Hussen et al., 2013), CD14+/CD16- cells designated as classical monocytes, 
and CD14-/CD16+ cells designated as nonclassical monocytes (Corripio-Miyar et al., 2015; 
Hussen et al., 2013). The mean percentage of CD3-/CD335+, CD3-/CD21+, CD3-/CD14+ and 
CD3-/CD16+ cells was 0.5% (± 0.4%), 7.1% (± 3.3%), 1.7% (± 0.4%), and 0.3% (± 0.1%) of 
all leukocytes, respectively (Table 8.3). 
 
A study in periparturient dairy cattle, in which the CD21 surface marker was used to identify 
B lymphocytes, calculated the percentage of B lymphocytes in peripheral blood to be 5-10% 
of all lymphocytes (Bromfield et al., 2018). Thus, the percentage of B lymphocytes of all 
leukocytes will be lower than this, as observed in this study. However, as previously 
mentioned, the lactation stage of cattle influences leukocyte counts in peripheral blood 
making direct comparisons difficult (Kulberg et al., 2002). Moreover, leukocytes, especially 
NK cells and monocytes, constitute only a small percentage of the total population of cells in 
cattle peripheral blood and percentages fluctuate regularly (Roland et al., 2014; Hamilton et 
al., 2017). Furthermore, only a small proportion of NK cells circulate in peripheral blood 
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Figure 8.1 Representative flow cytometric scatter plots of ex vivo cattle leukocytes from 





stable flow stream of cells, B) Forward scatter area (FSC-A) versus forward scatter height 
(FSC-H) scatter plot with a gate on single cells, C) FSC-A versus side scatter area (SCC-A) 
scatter plot with a gate on all cells excluding cell debris, D) Viability stain versus SSC-A 
scatter plot with a gate on viable cells, E) Alexa Fluor® 700 (CD3) versus SSC-A scatter plot 
with a gate on CD3- cells, a gate on CD3+ cells, and a gate to exclude selected cells 
appearing to be CD3+, F) Alexa Fluor® 647 (CD4) versus Alexa Fluor® 700 (CD3) scatter 
plot with a gate on CD3+/CD4+ cells and a gate on CD3+/CD4- cells, G) PE (CD335) versus 
Alexa Fluor® 700 (CD3) scatter plot with a gate on CD3+/CD335+ cells, H) PE (CD335) 
versus Alexa Fluor® 700 (CD3) scatter plot with a gate on CD3-/CD335+ cells, I) APC/Cy7 
(CD14) versus FITC (CD16) scatter plot with a gate on CD3-/CD21+ cells and J) APC/Cy7 
(CD14) versus FITC (CD16) scatter plot with a gate on CD3-/CD14+ cells and a gate on 
CD3-/CD16+ cells. 
 
A neutrophil surface marker was not included in the panel of antibodies optimised in this 
study. In humans, neutrophils are one of the key cellular sources of IP-10 (Gasperini et al., 
1999) and therefore, the exclusion of cell surface markers was used to try to identify bovine 
neutrophils in this study. Specifically, CD3-/CD335-/CD21-/CD14-/CD16- cells were 
identified and designated as potential neutrophils (data not shown). The mean percentage of 
these cells was 55.7% (± 12.6%) of all leukocytes (Table 8.3). However, in peripheral blood 
of adult cattle, the neutrophil-to-lymphocyte ratio is approximately 1:2 with neutrophils being 
the second largest leukocyte population after lymphocytes (Kim et al., 2016; Roland et al., 
2014). Moreover, FSC-A versus SSC-A scatter plot of these designated neutrophils indicated 
no uniform dispersion of cells based on size and granularity (data not shown). Based on these 
findings, the CD3-/CD335-/CD21-/CD14-/CD16- cells that were identified as potential 





Table 8.3 The percentage of cell populations characterized by phenotype as a percentage of total leukocytes in 10 ex vivo cattle whole blood 
samples. 
Cow ID CD3+ exclude CD3+ 
CD3+   
CD3- 
CD3-     
CD4+ CD4- CD335+ CD335+ CD21+ CD14+ CD16+ CD335-/CD21-/CD14-/CD16- 
1 0.6 23.6 6.7 16.8 0.5 73.3 0.5 5.1 1.4 0.2 68.6 
2 0.3 26.3 7.2 18.8 0.9 68.6 0.2 5.2 1.3 0.3 72.1 
3 0.1 33.4 13.1 20.2 0.3 64.7 1.4 13.9 1.6 0.3 55.1 
4 0.8 62.0 23.3 38.3 0.7 35.3 0.3 4.3 1.9 0.1 48.2 
5 1.0 23.9 7.0 16.8 0.7 72.9 0.2 5.9 1.3 0.1 67.8 
6 1.6 63.6 25.5 37.8 1.9 32.6 0.8 2.9 1.5 0.2 40.2 
7 0.1 36.9 12.0 24.2 3.2 60.4 0.6 11.3 2.1 0.2 48.9 
8 0.9 30.4 9.4 20.8 0.6 66.7 0.4 6.6 2.3 0.5 62.2 
9 0.6 32.1 8.2 23.7 0.8 63.6 0.3 8.2 2.0 0.3 59.2 
10 1.0 59.7 24.3 35.0 0.8 36.6 0.2 6.4 1.8 0.3 34.3 
Mean 0.7 36.9 12.5 24.2 1.1 59.8 0.5 7.1 1.7 0.3 55.7 
SD 0.5 16.2 7.7 8.5 0.9 16.1 0.4 3.3 0.4 0.1 12.6 





2.2. IP-10 production 
All cell subsets displayed an IP-10 signal, however in each cell subset, no significant 
difference was observed when the median proportions of unstimulated and stimulated 
cells displaying an IP-10 signal were compared (Figure 8.2). This suggests the IP-10 
signal observed may not have been related to the cytokine IP-10, and was due to non-
specific binding of either the biotinylated anti-IP-10 antibody or PE-Cy™7-
conjugated streptavidin. Notably, the proportion of cells in each cell subset displaying 
an IP-10 signal in both unstimulated and stimulated sample were similar for all 
animals (Figure 8.2). This suggests the reagent that caused the non-specific binding, 
bound to the same cellular component in the unstimulated and stimulated samples. 
The molecules biotin and streptavidin have a high affinity for one another (Weber et 
al., 1989), and so it is unlikely that PE-Cy™7-conjugated streptavidin would have 
bound to anything other than the biotinylated anti-IP-10 antibody. Therefore, it seems 
probable that the biotinylated anti-IP-10 antibody bound to an unknown cellular 
component, but this cannot be confirmed. The mean fluorescent intensity of all 
unstimulated and stimulated samples in the various cell subsets did not differ, 
indicating no upregulation of the cellular component causing an IP-10 signal (data not 
shown).  
 
A limitation of this study included detecting the cytokine IP-10. A bovine anti-IP-10 
antibody directly conjugated to a fluorophore was not available at the time this study 
was designed, and therefore a biotinylated anti-IP-10 antibody was used in 
combination with PE-Cy™7-conjugated streptavidin. This indirect method of 
labelling IP-10 may have resulted in an amplification of signal as many streptavidin 





specific binding is more likely to occur. Moreover, dairy cattle may not be the most 
suitable animals to use to investigate IP-10 production in leukocyte subsets, as the 
periparturient period and stage of lactation may influence frequencies of leukocytes. 
Additionally, neutrophils are a major cellular source of IP-10 in humans (Cassatella et 
al., 1997; Gasperini et al., 1999) and therefore, future studies investigating IP-10 
production in cattle and buffaloes should include a neutrophil surface maker such as 





























































Figure 8.2 The proportion of leukocyte populations characterized by phenotype as a 
percentage of the parent cell population eliciting an IP-10 signal. The IP-10 antibody 
signal in unstimulated (●) and pokeweed mitogen stimulated (▲) cattle whole blood 
of 10 cattle. The * indicates CD3-/CD335-/CD21-/CD14-/CD16- cells. Horizontal bars 





In this study, immunophenotyping was used to identify cattle leukocytes subsets. 
Although the cytokine IP-10 could not be detected, this pilot study provides a 
foundation for future research to investigate which leukocytes produce IP-10 in cattle 
and buffalo peripheral blood.  
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Appendix 8.1  
 
 
Figure 8.1 Titration of anti-CD3 [CD3-12] (Alexa Flour® 700) on cattle whole blood 
after red cell lysis. 
 
Figure 8.2 Titration of anti-CD4 [CC8] (Alexa Flour® 647) on cattle whole blood 

















































Figure 8.3 Titration of anti-CD21 [LT21] (PE/Cy5®) on cattle whole blood after red 
cell lysis. 
 













































Figure 8.5 Titration of anti-CD16 [KD1] (FITC) on cattle whole blood after red cell 
lysis. 
 

















































Figure 8.7 Titration of PE-Cy™7 streptavidin on cattle whole blood after red cell 
lysis. 
 

















































Figure 8.9 Titration of Fixable Viability Stain (BV510) on cattle whole blood after 
























Chapter 9 : General discussion 
 
This chapter aims to synthesise all the results from the previous chapters and to 






The diagnostic performance of CMI-based assays, namely the SCITT and in vitro 
cytokine release assays, to detect M. bovis infection in buffaloes are suboptimal. The 
development of novel tests and the optimisation of established tests with improved 
diagnostic performances are urgently required. The feasibility of performing a test is 
as important as the performance and therefore, both features need to be considered 
when evaluating a new test. Moreover, it is unlikely that a single test will have the 
desired level of performance, and so tests can be combined to increase Se or Sp 
(Gormley et al., 2006). In addition, the required performance parameters of a test will 
depend on the population being tested and the testing goals, i.e. screening versus 
confirmation of infection (Cousins and Florisson, 2005), and for different 
circumstances (high or low infection prevalence), interpretation of a test requires 
modification or a different test needs to be utilised. A holistic approach that 
incorporates bTB history, testing goals, infection prevalence and exposure risk of the 
population being tested will determine what test(s) would be most suitable and 
effective. This thesis describes novel CMI-based approaches to diagnose M. bovis 
infection in African buffaloes. 
 
QFT IGRA 
The QFT IGRA, using the QFT stimulation system in combination with the newly 
available commercial ruminant-specific cattletype® IFN-gamma ELISA, is a highly 
practical blood-based assay, with high Sp but relatively poor Se to detect M. bovis 
infection in buffaloes. It has been previously reported that the Sp of IGRAs are 
improved by using specific mycobacterial peptides (Parsons et al., 2011), with a 
possible decrease in Se (Goosen et al., 2014). The most accurate way to calculate the 





prevalence (Trevethan, 2017). Therefore, using samples from a small unbiased 
buffalo herd with high prevalence, the Se of the QFT IGRA was calculated to be poor, 
while the Se was overestimated in test-positive culture-confirmed buffaloes due to 
selection bias. Throughout this thesis, the Sp of assays were calculated using 
historical M. bovis-unexposed buffalo populations and not culture-negative M. bovis-
endemic controls, as mycobacterial culture is an imperfect gold standard (de la Rua-
Domenech et al., 2006). Thus, the QFT IGRA would be best utilised as a test in 
buffalo herds with no history of bTB, where the goal of testing is to limit false-
positive test results by using highly specific tests. Moreover, the standardised and 
commercially available components of the QFT IGRA will simplify future validation 
and enable assay reproducibility between laboratories. 
 
QFT IPRA 
Measuring the cytokine IP-10 in the QFT system, namely in the QFT IPRA, detected 
a greater number of culture-confirmed buffaloes than the QFT IGRA, however the Se 
of the IPRA remained suboptimal to detect M. bovis infection in buffaloes. It has been 
previously reported that measuring IP-10 in the QFT system improves the Se of 
detection in buffaloes compared to IFN-γ (Goosen et al., 2015), as IP-10 is a more 
sensitive biomarker since the cytokine is produced more than 2000-fold compared to 
IFN-γ (McInnis et al., 2005). Thus, the decrease in Se of the QFT IGRA as a result of 
using specific mycobacterial peptides in the QFT system (Goosen et al., 2014) is 
compensated in the IPRA by increased Se of this assay. Moreover, the QFT IPRA 
detects recently infected buffaloes as IP-10 can be measured at an earlier stage of 
infection when IFN-γ may not yet be detectable (Ruhwald et al., 2007). This is 





test results presented with no or early macroscopic pathology. In addition, as for other 
species, the measurement of IP-10 in the IPRA did not compromise the diagnostic Sp 
of the test (Ruhwald et al., 2009; Parsons et al., 2016). Thus, the QFT IPRA would be 




Parallel interpretation of the SCITT and Bovigam® IGRA identified all test-positive 
culture-confirmed buffaloes, significantly more buffaloes than each individual test 
identified, indicating an improvement in the detection of infected buffaloes. In 
agreement, in cattle, the Bovigam® IGRA is used as an ancillary test to the SCITT to 
improve the detection of M. bovis infection (de la Rua-Domenech et al., 2006) and a 
study advocated the parallel use of the SCITT and Bovigam® IGRA to maximise the 
detection of M. bovis-infected animals (Gormley et al., 2006). However, the use of 
this parallel testing strategy in buffaloes is limited by: i) the use of PPDs that result in 
cross-reactive immune responses to non-tuberculous mycobacteria (Michel, 2008); ii) 
the SCITT requirement for animals to be chemically immobilised twice and held 
captive during this time (Parsons et al., 2011); iii) the SCITT being subject to operator 
bias and error (A. McCall, personal communication); iv) the SCITT causing in vivo 
sensitization (Clarke et al., 2018) or desensitization which affects future test results; 
and v) the need for Bovigam® IGRA stimulations to be performed by skilled 
technicians, which cannot be easily performed in the field (Michel et al., 2011). 
Therefore, development of a blood-based assay, which only requires one 





can be performed in the field and contains specific mycobacterial antigens, would be 
beneficial for bTB testing of buffaloes. 
 
Parallel interpretation of the QFT assays, the IGRA and IPRA, identified all M. bovis-
infected buffaloes which was more than the individual QFT assays identified. It has 
been previously reported in humans and cattle that the parallel measurement of 
antigen-specific IFN-γ and IP-10 improves the detection of Mtb and M. bovis 
infection, respectively (Ruhwald et al., 2008; Coad et al., 2019). However, the lower 
Se of the QFT assays in parallel calculated in a small unbiased buffalo herd with high 
prevalence, indicates the Se is lower than previously reported. Importantly, the Sp of 
the individual QFT assays were maintained when the assays were interpreted in 
parallel. These findings indicate this in vitro parallel testing strategy, where only one 
set of QFT whole blood stimulation tubes are required in which two biomarkers are 
measured from the same plasma sample, should be used to increase detection of M. 
bovis-infected buffaloes while maintaining Sp and simplifying the testing procedure. 
Moreover, since there is no in vivo sensitization, these tests can be repeated without a 
waiting period, unlike the SCITT (Clarke et al., 2018). This advances our diagnostic 
approach to bTB diagnosis in that the parallel interpretation of tests may increase Se 
for optimal detection of infected buffaloes. However, further research into different 
interpretations of test combinations are required to see if Se can be improved.  
  
bTB Pathology  
The [IP-10Nil] and [IFN-γNil] were higher in buffaloes with culture-confirmed 
pathological lesions than uninfected controls, indicating the cytokines IP-10 and IFN-





in infected buffaloes. Therefore, the cytokines IP-10 and IFN-γ may be biomarkers of 
disease in buffaloes, as previously shown in humans (Whittaker et al., 2008; Hasan et 
al., 2009; Chegou et al., 2016), although additional investigation is required.  
 
In culture-confirmed buffaloes, the [IFN-γNil] and [IFN-γTB] - [IFN-γNil] values 
increased with lesion score, suggesting that the magnitude of unstimulated and 
antigen-stimulated IFN-γ indicate the degree of pathology in M. bovis-infected 
buffaloes. In humans, unstimulated IFN-γ concentrations increase during the 
progression of active TB disease (Hasan et al., 2009) and in humans, cattle and 
badgers, antigen-stimulated IFN-γ concentrations and disease severity are correlated 
(Vordermeier et al., 2002; Sahiratmadja et al., 2007; Tomlinson et al., 2015). Further 
investigation into quantification of [IFN-γNil] and [IFN-γTB] - [IFN-γNil] to determine 
cutoff values that are indicative bTB pathology in buffaloes will be valuable for 
detecting bTB disease. 
 
In M. bovis-infected culture-confirmed IPRA-negative IGRA-positive buffaloes, a 
significantly greater proportion of animals had evidence of pathology compared to 
those with NVL. Buffaloes with bTB lesions may produce higher [IP-10Nil], thus 
decreasing the IP-10 differential value between antigen-stimulated and unstimulated 
samples, resulting in an IPRA-negative result. This was supported by the observation 
that 5 of the 12 IPRA-negative IGRA-positive buffaloes with bTB pathology had 
higher [IP-10Nil] compared to [IP-10TB]. Therefore, IPRA results with high [IP-10Nil] 
should be regarded as inconclusive and not test-negative, whereas a buffalo that is 
IPRA-negative IGRA-positive should be suspected of having bTB pathology, if the 





the QFT Nil tubes when interpreting the final QFT assay results as this may provide 
extra information on the infection status and pathological state of the buffalo.  
 
Immunobiology of IP-10 production  
In cattle and buffaloes, the cellular source of IP-10 is unknown. Therefore, in order to 
understand the mechanism behind elevated IP-10 in some unstimulated buffalo whole 
blood samples, the cellular source of IP-10 was investigated in cattle, with the 
intention of using the optimised method to investigate IP-10 production in buffaloes. 
In humans, IP-10 has numerous cellular sources including antigen-presenting cells 
and lymphocytes (Gasperini et al., 1999; Hoff et al., 2015). Multiplex flow cytometry 
was used to determine the phenotype of immune cells that produce IP-10 in cattle. An 
IP-10 signal was detected in all cell phenotypes and no differences were observed 
between stimulated and unstimulated samples. Therefore, we could not conclude that 
the signal was specific to IP-10 and we were unable to identify the immune cells that 
produce the cytokine IP-10 in cattle.  
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The QFT system is an innovative platform to detect M. bovis infection in buffaloes 
utilizing field-friendly whole blood stimulation tubes and specific mycobacterial 
antigens that elicit highly specific cell-mediated immune responses. The QFT IGRA, 
combining the QFT system and novel cattletype® IFN-gamma ELISA, is a practical 
useful assay with high Sp that would especially have value for testing M. bovis-
unexposed herds to reduce the risk of false-positive test results. The measurement of 
the chemokine IP-10 in the QFT system increases the detection of M. bovis-infected 
buffaloes compared to IFN-γ, and is able to detect recently infected buffaloes that 
IGRAs may not. Notably, when the cytokines IP-10 and IFN-γ are measured in 
parallel in the QFT system, the detection of M. bovis-infected buffaloes is maximised 
while Sp is maintained and the test procedure is simplified using solely blood-based 
assays and a single stimulation platform. Finally, the magnitude of IP-10 and IFN-γ 
concentrations in QFT-processed whole blood may offer additional information as 
indicators of bTB pathology in buffaloes, providing a new insight into the disease 
status of infected buffaloes.  
  
Future directions 
Future investigations of the diagnostic performances of assays to detect M. bovis 
infection in African buffaloes should use unbiased sample populations with known 
infection prevalences to avoid overestimating performance metrics and should include 
buffalo herds with varying infection prevalences to determine the performances of 
assays in different populations. Moreover, investigations into different interpretations 
of the same test in buffalo populations with varying infection prevalences will allow 
the adaption of a single test for use in multiple populations, i.e. calculating different 





investigating the performance of tests in different stages of M. bovis infection and 
disease will confirm whether IP-10 is produced during early infection before IFN-γ 
becomes detectable and whether elevated levels of IP-10 are indicative of disease in 
buffaloes. Future characterization of the immunobiology of IP-10 production in cattle 
and buffaloes will enable a deeper understanding of the mechanism behind 
unstimulated production of this cytokine in M. bovis infection in bovids. 
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